Document:

Voting Agreement

 Exhibit 10.1 

VOTING AGREEMENT 

This VOTING AGREEMENT (this “Agreement”) is entered into as of June 30, 2010, by and among Celgene
Corporation, a Delaware corporation (“Parent”), Artistry Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Sub”), and the Persons whose names are set forth on the signature pages
hereto under the caption “Stockholders” (each individually a “Stockholder” and, collectively, the “Stockholders”). 

W I T N E S S E T H: 

WHEREAS, as of the date of this Agreement, each Stockholder owns the number of shares of Common Stock, par value $.001
per share (the “Company Stock”), of Abraxis BioScience, Inc., a Delaware corporation (the “Company”), set forth opposite such Stockholder’s name on Schedule A attached hereto; 

WHEREAS, concurrently herewith, Parent, Sub and the Company are entering into an Agreement and Plan of Merger, dated as
of this date (the “Merger Agreement”), pursuant to which Sub will merge with and into the Company and the Company will survive as a wholly-owned subsidiary of Parent (the “Merger”), and each share of Company Stock
(other than Excluded Company Shares) will be converted into the right to receive the Merger Consideration, in accordance with the terms of, and subject to the conditions set forth in, the Merger Agreement; and 

WHEREAS, as a condition to the willingness of Parent and Sub to enter into the Merger Agreement, and as an inducement and
in consideration therefor, Parent and Sub have required that the Stockholders agree, and the Stockholders have agreed, to enter into this Agreement. 

NOW, THEREFORE, in consideration of the foregoing and the mutual premises, representations, warranties, covenants and
agreements contained in this Agreement, the parties, intending to be legally bound, hereby agree as follows: 
 ARTICLE I 

 DEFINITIONS 

SECTION 1.1 Defined Terms. For purposes of this Agreement, terms used in this Agreement that are defined in
the Merger Agreement but not in this Agreement shall have the respective meanings ascribed to them in the Merger Agreement. 

SECTION 1.2 Other Definitions. For purposes of this Agreement: 

(a) “Company Options” means options to acquire Company Stock granted to a Stockholder by the Company and
held by a Stockholder as of the date of this Agreement as set forth on Schedule A. 

 (b) “Company RSUs” means restricted stock units with
respect to Company Stock granted to a stockholder by the Company and held by a Stockholder as of the date of this Agreement as set forth on Schedule A. 

(c) “Immediate Family” means lineal descendants (whether by blood or marriage), ancestral forebears,
current and former spouses, and persons related by blood, adoption or marriage to any of the foregoing. 
 (d)
“New Shares” means any shares of Company Stock (other than Owned Shares) acquired by a Stockholder at any time during the Voting Period. 

(e) “Option Shares” means any shares of Company Stock issued or issuable upon exercise of Company
Options. 
 (f) “Owned Shares” means all of the shares of Company Stock owned by such
Stockholder as of the date of this Agreement as set forth on Schedule A. 
 (g) “Permitted
Transferee” means PSS and any PSS Entity or any charitable foundation or organization, in each case only if such parties agree to be bound by the terms of this Agreement. 

(h) “PSS” means Dr. Patrick Soon-Shiong. 

(i) “PSS Entity” means any trust for the benefit of PSS or any members of PSS’ Immediate Family and
any other entity in which PSS or any members of PSS’ Immediate Family separately or collectively hold, directly or indirectly, a majority of the outstanding equity interests. 

(j) “Representative” means, with respect to any particular Person, the officers, directors, employees,
trustees, investment bankers, attorneys and other advisors or representatives of such Person. 
 (k)
“RSU Shares” means any shares of Company Stock issued or issuable upon vesting of Company RSUs. 

(l) “Transfer” means sell, transfer, tender, assign, pledge, encumber or otherwise dispose. 

(m) “Voting Period” means the period from and including the date of this Agreement through and including
the earliest to occur of (i) the Effective Time, and (ii) the termination of the Merger Agreement in accordance with its terms. 
  

 -2- 

 ARTICLE II 

VOTING AGREEMENT AND IRREVOCABLE PROXY 

SECTION 2.1 Agreement to Vote. 

(a) Each Stockholder hereby agrees that, during the Voting Period, such Stockholder shall vote or execute consents, as
applicable, with respect to the Owned Shares and any New Shares owned by such Stockholder as of the applicable record date (or cause to be voted or a consent to be executed with respect to the Owned Shares or any New Shares owned by such Stockholder
as of the applicable record date) in favor of the approval and adoption of the Merger Agreement and the transactions contemplated by the Merger Agreement, at any meeting (or any adjournment or postponement thereof) of, or in connection with any
proposed action by written consent of, the holders of Company Stock at or in connection with which any of the holders vote or execute consents with respect to any of the foregoing matters. 

(b) Subject to Section 3.2 hereof, each Stockholder hereby agrees that, during the Voting Period, such Stockholder
shall vote or execute consents, as applicable, with respect to the Owned Shares and any New Shares owned by such Stockholder as of the applicable record date (or cause to be voted or a consent to be executed with respect to the Owned Shares and any
New Shares owned by such Stockholder as of the applicable record date) against each of the matters set forth in clauses (i), (ii), (iii) and (iv) below at any meeting (or any adjournment or postponement thereof) of, or in connection with
any proposed action by written consent of, the holders of Company Stock at or in connection with which any of the holders vote or execute consents with respect to any of the following matters: 

(i) any merger agreement or merger (other than the Merger Agreement, the Merger or any business
combination or transaction with Parent or any of its affiliates), consolidation, combination, reorganization, recapitalization, dissolution, liquidation or winding up of or by the Company or any other business combination or extraordinary corporate
transaction involving the Company or any of its Subsidiaries, or any sale, lease or transfer of a material amount of assets of the Company or any of its Subsidiaries; 

(ii) any amendment of the Company’s certificate of incorporation, as amended to date, unless such
amendment is consented to by Parent; 
 (iii) any action, proposal, transaction or agreement that
would reasonably be expected to result in a breach in any respect of any covenant, representation or warranty or any other obligation or agreement of the Company contained in the Merger Agreement or of such Stockholder contained in this Agreement;
and 
 (iv) any action, proposal, transaction or agreement involving the Company or any of its
Subsidiaries that would reasonably be expected to prevent, 
  

 -3- 

 
impede, frustrate, interfere with, delay, postpone or adversely affect the Merger and the other transactions contemplated by the Merger Agreement. 

(c) Any vote required to be cast or consent required to be executed pursuant to this Section 2.1 shall be cast or
executed in accordance with the applicable procedures relating thereto so as to ensure that it is duly counted for purposes of determining that a quorum is present (if applicable) and for purposes of recording the results of that vote or consent.
Nothing contained in this Section 2.1 shall require any Stockholder to vote or execute any consent with respect to any Option Shares or RSU Shares not issued to the Stockholder prior to the applicable record date for that vote or consent.

 SECTION 2.2 Grant of Irrevocable Proxy. Each Stockholder hereby irrevocably appoints Parent and
any designee of Parent, and each of them individually, as such Stockholder’s proxy and attorney-in-fact, with full power of substitution and resubstitution, to vote or execute consents during the Voting Period, with respect to the Owned Shares
and any New Shares owned by such Stockholder as of the applicable record date, in each case solely to the extent and in the manner specified in Section 2.1. This proxy is given to secure the performance of the duties of such Stockholder under
this Agreement, and its existence will not be deemed to relieve such Stockholder of its obligations under Section 2.1. Other than as described in this Section 2.2 and other than the granting of proxies to vote Owned Shares or
New Shares with respect to the election of directors and ratification of the appointment of the Company’s auditors at the Company’s annual meeting of Stockholders, in accordance with the recommendation of the Board of Directors of the
Company, such Stockholder shall not directly or indirectly grant any Person any proxy (revocable or irrevocable), power of attorney or other authorization with respect to any of such Stockholder’s Owned Shares or New Shares. For Owned Shares or
New Shares as to which the Stockholder is the beneficial but not the record owner, such Stockholder will cause any record owner of such Owned Shares or New Shares to grant to Parent a proxy to the same effect as that contained in this Section
2.2. 
 SECTION 2.3 Nature of Irrevocable Proxy. The proxy and power of attorney
granted pursuant to Section 2.2 by each Stockholder shall be irrevocable during the Voting Period, shall be deemed to be coupled with an interest sufficient in law to support an irrevocable proxy and shall revoke any and all prior proxies
granted by such Stockholder with regard to such Stockholder’s Owned Shares or any New Shares acquired by such Stockholder, and such Stockholder acknowledges that the proxy constitutes an inducement for Parent and Sub to enter into the Merger
Agreement. The power of attorney granted by each Stockholder is a durable power of attorney and shall survive the bankruptcy, dissolution, death or incapacity of such Stockholder. The proxy and power of attorney granted hereunder shall terminate
only upon the expiration of the Voting Period. 
  

 -4- 

 ARTICLE III 

COVENANTS 

SECTION 3.1 Voting Period Restrictions. Each Stockholder agrees that such Stockholder shall not, during the
Voting Period, (i) Transfer any or all of such Stockholder’s Owned Shares or New Shares, or any interest therein, or enter into any agreement with respect to the Transfer of any or all of such Stockholder’s Owned Shares or New Shares,
or any interest therein, or (ii) except pursuant to the terms of this Agreement, grant any proxies or powers of attorney, deposit any Owned Shares or New Shares into a voting trust or enter into a voting agreement with respect to any Owned
Shares or New Shares; provided that the foregoing shall not prevent (a) the Transfer of Owned Shares or New Shares upon the death of such Stockholder pursuant to the terms of any trust or will of such Stockholder or by the laws of
intestate succession, but only if, and any such Transfer shall be void unless, the transferee executes and delivers to Parent an agreement to be bound by the terms of this Agreement to the same extent as such Stockholder, (b) the Transfer of
Owned Shares or New Shares to a Permitted Transferee, (c) the Transfer of Owned Shares or New Shares solely in connection with the payment of the exercise price and/or the satisfaction of any tax withholding obligation arising from the exercise
of any Company Option or the vesting of any Company RSU, (d) the conversion of any Owned Shares and New Shares into the right to receive the Merger Consideration pursuant to the Merger in accordance with the terms of the Merger Agreement, or
(e) the granting of proxies to vote Owned Shares or New Shares with respect to the election of directors and ratification of the appointment of the Company’s auditors at the Company’s annual meeting of Stockholders, in accordance with
the recommendation of the Board of Directors of the Company. 
 SECTION 3.2 No Shop Obligations of
Each Stockholder. Each Stockholder agrees that such Stockholder shall not, and that such Stockholder shall use its reasonable best efforts to cause the Representatives of such Stockholder to not, directly or indirectly, (i) solicit,
initiate, or knowingly encourage the making, submission or announcement of any inquiry regarding, or any proposal or offer which would reasonably be expected to lead to, an Acquisition Proposal, (ii) enter into, participate, continue or
otherwise engage in discussions or negotiations with, or provide any non-public information to any Person (other than Parent, Sub and their Representatives) with respect to any inquiries regarding, or the making, submission or announcement of, an
Acquisition Proposal, or (iii) enter into or approve any letter of intent, agreement in principle, option agreement, share purchase agreement, acquisition agreement or similar agreement relating to an Acquisition Proposal; provided,
however, that each Stockholder may, and may authorize and permit any Representative of such Stockholder to, provide non-public information to, and participate in discussions or negotiations, with any Person if at such time such Stockholder
has been notified by the Company that the Board of Directors of the Company is permitted to provide non-public information to, or engage in discussions or negotiations with, such Person in accordance with the Merger Agreement. The Stockholder shall
immediately cease and cause to be terminated any ongoing solicitation, discussion or negotiation with any Person conducted prior to the date of this Agreement by the Stockholder or any of its Representatives with respect to any actual or potential
Acquisition Proposal. A Stockholder shall notify Parent orally and in writing promptly 
  

 -5- 

 
(and in any event within 24 hours) after receipt of any Acquisition Proposal or any request for information or inquiry which could reasonably be expected to lead to an Acquisition Proposal. The
written notice shall include the identity of the Person making such Acquisition Proposal, request or inquiry, the material terms of the Acquisition Proposal, request or inquiry (including any material written amendments or modifications, or any
proposed material written amendments or modifications, thereto), and the Stockholder shall keep Parent reasonably informed on a current basis of any material changes with respect to such Acquisition Proposal, request or inquiry. 

SECTION 3.3 General Covenants. Each Stockholder agrees that such Stockholder shall not: 

(a) enter into any agreement, commitment, letter of intent, agreement in principle, or understanding with any Person or
take any other action that violates or conflicts with or would reasonably be expected to violate or conflict with, or result in or give rise to a violation of or conflict with, such Stockholder’s covenants and obligations under this Agreement
or make any of its representations and warranties contained herein untrue or incorrect; or 
 (b) take any
action that could restrict or otherwise affect such Stockholder’s legal power, authority and right to comply with and perform such Stockholder’s covenants and obligations under this Agreement. 

SECTION 3.4 Stockholders’ Capacity. Parent and Sub acknowledge that no Stockholder is making any
agreement or understanding herein in such Stockholder’s capacity as a director or officer of the Company and that each Stockholder is executing this agreement solely in such Stockholder’s capacity as the owner of Company Stock and nothing
herein shall limit or affect any actions taken by such Stockholder in such Stockholder’s capacity as a director or officer of the Company. 

SECTION 3.5 Letter of Transmittal and Delivery of Merger Consideration. Parent agrees to provide the
Stockholders a copy of the letter of transmittal referenced in Section 2.2 of the Merger Agreement a reasonable time period prior to the anticipated Closing Date to allow the Stockholders to complete the letter of transmittal and provide such
letter of transmittal to the Paying Agent prior to or on the Closing Date. Parent agrees to use reasonable best efforts to cause the Paying Agent to deliver by wire transfer of immediately available funds the Merger Consideration to which the
Stockholders are entitled under the terms of the Merger Agreement on the same date as the Closing Date. 
 ARTICLE IV 

 REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDERS 

Each Stockholder hereby represents and warrants to Parent and Sub as follows: 

SECTION 4.1 Authorization. Such Stockholder has all power and authority (or legal capacity in the case of
an individual) to execute and deliver this Agreement and to perform its obligations hereunder. This Agreement has been duly and validly 

 

 -6- 

 
authorized, executed and delivered by such Stockholder and, assuming it has been duly and validly authorized, executed and delivered by Parent and Sub, constitutes a legal, valid and binding
obligation of such Stockholder, enforceable against such Stockholder in accordance with its terms, except to the extent that enforceability may be limited by (i) applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent
conveyance or other similar laws now or hereafter in effect relating to creditor’s rights generally, and (ii) general principles of equity. 

SECTION 4.2 Ownership of Shares. As of the date hereof, all Owned Shares, Company Options and Company RSUs
owned by such Stockholder are listed on Schedule A attached hereto. Such Stockholder (a) is the sole beneficial owner of all of the Owned Shares, Company Options and Company RSUs listed opposite such Stockholder’s name on
Schedule A hereto free and clear of any Liens, voting agreements or commitments of every kind that would reasonably be expected to violate or conflict with, or result in or give rise to a violation of or conflict with, or adversely affect the
exercise or fulfillment of, such Stockholder’s covenants and obligations under this Agreement, and (b) has the sole power to vote (or cause to be voted or consents to be executed) and to dispose of (or cause to be disposed of) such Owned
Shares without restriction, and no proxies through and including the date hereof given in respect of any or all of such Stockholder’s Owned Shares, Company Options or Company RSUs are irrevocable and any such proxies have been revoked.

 SECTION 4.3 No Conflicts. Except for a filing of an amendment to a Schedule 13D and a filing of
a Form 4 as required by the Exchange Act, (i) no filing with any Governmental Entity, and no authorization, consent or approval of any other Person is necessary for the execution of this Agreement by such Stockholder or the performance by such
Stockholder of such Stockholder’s obligations hereunder and (ii) none of the execution and delivery of this Agreement by such Stockholder, or the performance by such Stockholder of such Stockholder’s obligations hereunder shall
(A) result in, give rise to or constitute a violation or breach of or a default (or any event which with notice or lapse of time or both would become a violation, breach or default) under, or give to others any rights of termination, amendment,
acceleration or cancellation of, or result in the creation of a Lien on, any of the Owned Shares pursuant to any of the terms of any understanding, agreement, or other instrument or obligation to which such Stockholder is a party or by which such
Stockholder or any of such Stockholder’s Owned Shares are bound, or (B) violate any applicable law, rule, regulation, order, judgment, or decree applicable to such Stockholder, except for any of the foregoing as would not reasonably be
expected to impair such Stockholder’s ability to perform such Stockholder’s obligations under this Agreement in any material respect.  

ARTICLE V 

REPRESENTATIONS AND WARRANTIES OF PARENT AND SUB 

Each of Parent and Sub hereby represent and warrant to the Stockholders as follows: 

 

 -7- 

 SECTION 5.1 Authorization. Such party has all power and
authority to execute and deliver this Agreement and to perform its obligations hereunder. This Agreement has been duly and validly authorized, executed and delivered by such party and, assuming it has been duly and validly authorized, executed and
delivered by the Stockholders, constitutes a legal, valid and binding obligation of such party, enforceable against it in accordance with the terms of this Agreement. 

SECTION 5.2 No Conflicts. The execution and delivery of this Agreement by such party does not and the
performance of this Agreement by such party will not (i) conflict with, result in any violation of, require any consent under or constitute a default (whether with notice or lapse of time or both) under any mortgage, bond, indenture, agreement,
instrument or obligation to which it is a party or by which it or any of its properties is bound; (ii) violate any judgment, order, injunction, decree or award of any court, administrative agency or other Governmental Entity that is binding on
such party or any of its properties; or (iii) constitute a violation by such party of any law, regulation, rule or ordinance applicable to such party, in each case, except for any violation, conflict or consent as would not reasonably be
expected to materially impair the ability of such party to perform its obligations under this Agreement. 
 ARTICLE VI 

 TERMINATION 

This Agreement shall terminate upon the earliest to occur of (i) the Effective Time, (ii) any material
amendment to the Merger Agreement that is adverse to the Stockholders that has not been approved by the Stockholders (it being understood that any decrease in or change in form of the Merger Consideration shall constitute a material amendment to the
Merger Agreement that is adverse to the Stockholders), and (iii) the termination of the Merger Agreement in accordance with its terms. Upon the termination of this Agreement, neither Parent, Sub nor the Stockholders shall have any rights or
obligations hereunder and this Agreement shall become null and void and have no effect; provided, that, with respect to termination pursuant to clause (i) above, Sections 7.1, 7.3 and 7.5 through 7.12 shall survive such termination.
Notwithstanding the foregoing, termination of this Agreement shall not prevent any party from seeking any remedies (at law or in equity) against any other party for that party’s breach of any of the terms of this Agreement prior to the date of
termination.  
 ARTICLE VII 

MISCELLANEOUS 

SECTION 7.1 Publication. Each Stockholder hereby permits Parent, Sub and/or the Company to publish and
disclose in press releases, Schedule 13D filings, and the Proxy Statement/Prospectus (including all documents and schedules filed with the SEC) and any other disclosures or filings required under the Merger Agreement or by applicable Law such
Stockholder’s identity and ownership of shares of the Company Stock, the nature of such Stockholder’s commitments, arrangements and understandings pursuant to this Agreement and/or the text of this Agreement. 

 

 -8- 

 SECTION 7.2 Waiver of Appraisal Rights and Actions. Each
Stockholder hereby (i) waives any rights of appraisal or rights to dissent from the Merger or the adoption of the Merger Agreement that such Stockholder may have under applicable law and shall not permit any such rights of appraisal or rights
of dissent to be exercised with respect to such Stockholder’s Owned Shares, any New Shares, any Option Shares or any RSU Shares and (ii) agrees not to commence or participate in, and to take all actions necessary to opt out of any class in
any class action with respect to, any claim, derivative or otherwise, against Parent, Sub, the Company or any of their respective successors relating to the negotiation, execution or delivery of this Agreement or the Merger Agreement or the
consummation of the Merger, including any claim alleging a breach of any fiduciary duty of the Board of Directors of the Company in connection with the Merger Agreement or the transactions contemplated thereby. 

SECTION 7.3 Amendments, Waivers, etc. This Agreement may be amended by the parties at any time. This
Agreement may not be amended except by an instrument in writing signed on behalf of each of the parties. Except as provided in this Agreement, no action taken pursuant to this Agreement, including any investigation by or on behalf of any party,
shall be deemed to constitute a waiver by the party taking the action of compliance with any representations, warranties, covenants or agreements contained in this Agreement. The waiver by any party of a breach of any provision hereunder shall not
operate or be construed as a waiver of any prior or subsequent breach of the same or any other provision hereunder. 

SECTION 7.4 Enforcement of Agreement; Specific Performance. The Stockholders agree and acknowledge
that Parent and Sub would suffer irreparable damage in the event that any of the obligations of the Stockholders in this Agreement were not performed in accordance with its specific terms or if the Agreement was otherwise breached by the
Stockholders. It is accordingly agreed by the Stockholders that Parent shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, this being in
addition to any other remedy to which Parent may be entitled at law or in equity. 
 SECTION 7.5
Notices. Except for notices that are specifically required to be delivered orally, all notices, requests, claims, demands and other communications hereunder shall be in writing and shall be deemed given (a) on the date of
delivery, if delivered in person or by facsimile or e-mail (upon confirmation of receipt), (b) on the first Business Day following the date of dispatch, if delivered by a recognized overnight courier service (upon proof of delivery) or
(c) on the fifth Business Day following the date of mailing, if delivered by registered or certified mail, postage prepaid, return receipt requested, addressed as follows: 

(a) If to the Parent or Sub, addressed to it at: 

Celgene Corporation 

86 Morris Avenue 

Summit, New Jersey 07901 

Tel: 908.673.9000 
  

 -9- 

 Fax: 908.673.2769 

Attention: George Golumbeski, Senior Vice President Business 

 Development ggolumbeski@celgene.com 

with copies to: 

Celgene Corporation 

86 Morris Avenue 

Summit, New Jersey 07901 

Tel: 908.673.9000 

Fax: 908.673.2771 

Attention: Thomas Perone, Corporate Counsel 

 tperone@celgene.com 

and a copy (which shall not constitute notice) to: 

Jones Day 

3161 Michelson Drive 

Suite 800 

Irvine, CA 92612 

Tel: 949.851.3939 

Fax: 949.553.7539 

Attention: Jonn R. Beeson, Esq. 

 jbeeson@jonesday.com 

 Kevin Espinola, Esq. 

 kbespinola@jonesday.com 

(b) If to the Stockholders, addressed to them at: 

Abraxis BioScience Inc. 

11755 Wilshire Blvd., 20th Floor 

Los Angeles, CA 90025 

Tel: 310.883.1300 

Fax: 310.998.8553 

Attention: Dr. Patrick Soon-Shiong, Executive Chairman 

 pss@abraxisbio.com 

with copies to: 

Abraxis BioScience Inc. 

11755 Wilshire Blvd., 20th Floor 

Los Angeles, CA 90025 

Tel: 310.883.1300 

Fax: 310.998.8553 

Attention: Charles Kim, General Counsel 

 

 -10- 

  CKim@abraxisbio.com 

and a copy (which shall not constitute notice) to: 

Fried, Frank, Harris, Shriver & Jacobson LLP 

One New York Plaza 

New York, New York 10004 

Tel: 212.859.8000 

Fax: 212.859.4000 

Attention: Philip Richter, Esq. 

 philip.richter@friedfrank.com 

 Brian Mangino, Esq. 

 brian.mangino@friedfrank.com 

or to that other address as any party shall specify by written notice so given, and notice shall be deemed to have been delivered as of
the date so telecommunicated or personally delivered. 
 SECTION 7.6 Headings; Titles.
Headings and titles of the Articles and Sections of this Agreement are for the convenience of the parties only, and shall be given no substantive or interpretative effect whatsoever. 

SECTION 7.7 Severability. Any term or provision of this Agreement which is invalid or unenforceable
in any jurisdiction shall, as to that jurisdiction, be ineffective to the extent of this invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions of this Agreement or affecting the validity or
enforceability of any of the terms or provisions of this Agreement in any other jurisdiction. Upon determination that any term or other provision is invalid or incapable of being enforced, the parties shall negotiate in good faith to modify this
Agreement as to effect the original intent of the parties as closely as possible in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the extent possible. 

SECTION 7.8 Entire Agreement. This Agreement (together with the Merger Agreement, to the extent
referred to in this Agreement) and any documents delivered by the parties in connection herewith constitutes the entire agreement among the parties with respect to the subject matter of this Agreement and supersedes all prior agreements and
understandings among the parties with respect thereto. No addition to or modification of any provision of this Agreement shall be binding upon any party unless made in writing and signed by all parties. 

SECTION 7.9 Assignment; Binding Effect; No Third Party Beneficiaries; Further Action. Neither this
Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any of the parties. This Agreement shall be binding upon and shall inure to the benefit of Parent and Sub and their respective successors and assigns and shall
be binding upon the Stockholders and the Stockholders’ successors, assigns, heirs, executors and administrators. Notwithstanding anything contained in this Agreement to the contrary, nothing in this Agreement, expressed or implied, is intended

  

 -11- 

 
to confer on any Person (other than, in the case of Parent and Sub, their respective successors and assigns and, in the case of the Stockholders, the Stockholders’ successors, assigns,
heirs, executors and administrators) any rights, remedies, obligations or liabilities under or by reason of this Agreement. The Stockholders shall take any further action and execute any other instruments as may be reasonably requested by Parent to
effectuate the intent of this Agreement. 
 SECTION 7.10 Mutual Drafting. Each party has
participated in the drafting of this Agreement, which each party acknowledges is the result of extensive negotiations between the parties. This Agreement shall not be deemed to have been prepared or drafted by any one party or another or any
party’s attorneys. 
 SECTION 7.11 Governing Law and Consent to Jurisdiction. This Agreement
shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to its rules of conflict of laws. The Stockholders hereby irrevocably and unconditionally consent to submit to the jurisdiction of the federal
courts located in the State of Delaware or any Delaware state courts (and, if appropriate, appellate courts therefrom) in connection with any action or proceeding arising out of or relating to this Agreement and the transactions contemplated hereby
(and agree not to commence any suit, action or proceeding relating thereto except in those courts), waive any defense or objection they may have or hereafter have relating to the laying of venue of any suit, action or proceeding in any such courts
and agree not to plead or claim that any suit, action or proceeding brought therein has been brought in an inconvenient forum. 

SECTION 7.12 Counterparts; Facsimiles. This Agreement may be executed by the parties in separate
counterparts, each of which when so executed and delivered shall be an original, but all counterparts shall together constitute one and the same instrument. Each counterpart may consist of a number of copies each signed by less than all, but
together signed by all of the parties. This Agreement or any counterpart may be executed and delivered by facsimile copies, each of which shall be deemed an original. 

(Signature page follows.) 
  

 -12- 

 IN WITNESS WHEREOF, Parent, Sub and the Stockholders have caused this
Agreement to be duly executed as of the day and year first above written. 
  

							
	CELGENE CORPORATION
			
		 	By:	 	 /s/ Robert J. Hugin

		 		 	Name:	 	Robert J. Hugin
		 		 	Title:	 	Chief Executive Officer
	
	ARTISTRY ACQUISITION CORP.
			
		 	By:	 	 /s/ Sandesh Mahatme

		 		 	Name:	 	Sandesh Mahatme
		 		 	Title:	 	Secretary and Treasurer

 

					
	STOCKHOLDERS:
	
	DR. PATRICK SOON-SHIONG
	
	 /s/ Patrick Soon-Shiong

	
	CALIFORNIA CAPITAL LP
		
	By:	 	Themba LLC, its general partner
		
	By:	 	 /s/ Steven H. Hassan

		 	Name:	 	Steven H. Hassan
		 	Title:	 	Manager
	
	PATRICK SOON-SHIONG 2009 GRAT 1
		
	By:	 	 /s/ Patrick Soon-Shiong

		 	Name:	 	Patrick Soon-Shiong
		 	Title:	 	Trustee

 [Signature Page to Voting
Agreement] 

					
	PATRICK SOON-SHIONG 2009 GRAT 2
		
	By:	 	 /s/ Patrick Soon-Shiong

		 	Name:	 	Patrick Soon-Shiong
		 	Title:	 	Trustee
	
	MICHELE B. SOON-SHIONG GRAT 1
		
	By:	 	 /s/ Michele B. Chan Soon-Shiong

		 	Name:	 	Michele B. Chan Soon-Shiong
		 	Title:	 	Trustee
	
	MICHELE B. SOON-SHIONG GRAT 2
		
	By:	 	 /s/ Michele B. Chan Soon-Shiong

		 	Name:	 	Michele B. Chan Soon-Shiong
		 	Title:	 	Trustee
	
	SOON-SHIONG COMMUNITY PROPERTY REVOCABLE TRUST
		
	By:	 	 /s/ Patrick Soon-Shiong

		 	Name:	 	Patrick Soon-Shiong
		 	Title:	 	Trustee
		
	By:	 	 /s/ Michele B. Chan Soon-Shiong

		 	Name:	 	Michele B. Chan Soon-Shiong
		 	Title:	 	Trustee

 [Signature Page to Voting
Agreement] 

					
	THE CHAN SOON-SHIONG FAMILY FOUNDATION
		
	By:	 	 /s/ Charles Kenworthy

		 	Name:	 	Charles Kenworthy
		 	Title:	 	Executive Vice President

 [Signature
Page to Voting Agreement] 

					
	CALIFORNIA CAPITAL TRUST
		
	 By:
	 	 /s/ Patrick Soon-Shiong

		 	Name:	 	Patrick Soon-Shiong
		 	Title:	 	Trustee
		
	By:	 	 /s/ Michele B. Chan Soon-Shiong

		 	Name:	 	Michele B. Chan Soon-Shiong
		 	Title:	 	Trustee
		
	By:	 	 /s/ Steven H. Hassan

		 	Name:	 	Steven H. Hassan
		 	Title:	 	Trustee

 I acknowledge that I have read the Voting
Agreement, dated as of June 30, 2010, among by and among Celgene Corporation, a Delaware corporation, Artistry Acquisition Corp., a Delaware corporation, and the other parties thereto, and understand its contents. I am aware that by its
provisions all or part of the shares of common stock, par value $.001 per share, of Abraxis BioScience, Inc., a Delaware corporation, held by my spouse, Dr. Patrick Soon-Shiong, including my community interest in such shares, if any, are
subject to the provisions of such agreement. 
  

	
	MICHELE B. CHAN SOON-SHIONG
	
	/s/ Michele B. Chan Soon-Shiong

[Signature Page to Voting Agreement] 

 SCHEDULE A 

STOCKHOLDERS 
  

								
	 Stockholder
	  	Owned Shares	  	Company Options	 	 	Company RSUs
				
	 Dr. Patrick Soon-Shiong

Dr. Soon-Shiong may be deemed the beneficial owner
	  		  	183,635
	1 
	 	206,204
				
	 California Capital LP
	  	7,987,159	  			 	
				
	 Patrick Soon-Shiong 2009 GRAT 1
	  	5,759,109	  			 	
				
	 Patrick Soon-Shiong 2009 GRAT 2
	  	5,759,109	  			 	
				
	 Michele B. Soon-Shiong GRAT 1
	  	5,759,109	  			 	
				
	 Michele B. Soon-Shiong GRAT 2
	  	5,759,110	  			 	
				
	 Soon-Shiong Community Property Revocable Trust
	  	716,916	  			 	
				
	 California Capital Trust
	  	144,555	  			 	
				
	 The Chan Soon-Shiong Family Foundation
	  	1,301,000	  			 	
		  	 	  	 	 	 	 
				
	 Total:
	  	33,186,067	  	183,635	  	 	206,204
		  	 	  	 	 	 	 

  

	1
	 Includes 29,545 vested and 154,090 unvested Company Options as of the date hereof.Form of Contingent Value Rights Agreement

 Exhibit 10.2 

FORM OF 

CONTINGENT VALUE RIGHTS AGREEMENT 

by and between 

CELGENE CORPORATION 

and 

[TRUSTEE] 

Dated as of [—], 2010 

 TABLE OF CONTENTS 

 

					
	 ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION
	  	1
			
	 Section 1.1
	  	Definitions.	  	1
			
	 Section 1.2
	  	Compliance and Opinions.	  	13
			
	 Section 1.3
	  	Form of Documents Delivered to Trustee.	  	14
			
	 Section 1.4
	  	Acts of Holders.	  	14
			
	 Section 1.5
	  	Notices, etc., to Trustee and Company.	  	15
			
	 Section 1.6
	  	Notice to Holders; Waiver.	  	16
			
	 Section 1.7
	  	Conflict with Trust Indenture Act.	  	16
			
	 Section 1.8
	  	Effect of Headings and Table of Contents.	  	16
			
	 Section 1.9
	  	Benefits of Agreement.	  	16
			
	 Section 1.10
	  	Governing Law.	  	16
			
	 Section 1.11
	  	Legal Holidays.	  	17
			
	 Section 1.12
	  	Separability Clause.	  	17
			
	 Section 1.13
	  	No Recourse Against Others.	  	17
			
	 Section 1.14
	  	Counterparts.	  	17
			
	 Section 1.15
	  	Acceptance of Trust.	  	17
		
	ARTICLE 2 SECURITY FORMS	  	17
			
	 Section 2.1
	  	Forms Generally.	  	17
		
	ARTICLE 3 THE SECURITIES	  	18
			
	 Section 3.1
	  	Title and Terms.	  	18
			
	 Section 3.2
	  	Registrable Form.	  	19
			
	 Section 3.3
	  	Execution, Authentication, Delivery and Dating.	  	20
			
	 Section 3.4
	  	Temporary Securities.	  	20
			
	 Section 3.5
	  	Registration, Registration of Transfer and Exchange.	  	21
			
	 Section 3.6
	  	Mutilated, Destroyed, Lost and Stolen Securities.	  	21
			
	 Section 3.7
	  	Payments with respect to CVR Certificates.	  	22
			
	 Section 3.8
	  	Persons Deemed Owners.	  	22
			
	 Section 3.9
	  	Cancellation.	  	22
		
	ARTICLE 4 THE TRUSTEE	  	23

  

 i 

					
	 Section 4.1
	  	Certain Duties and Responsibilities.	  	23
			
	 Section 4.2
	  	Certain Rights of Trustee.	  	23
			
	 Section 4.3
	  	Notice of Default.	  	24
			
	 Section 4.4
	  	Not Responsible for Recitals or Issuance of Securities.	  	25
			
	 Section 4.5
	  	May Hold Securities.	  	25
			
	 Section 4.6
	  	Money Held in Trust.	  	25
			
	 Section 4.7
	  	Compensation and Reimbursement.	  	25
			
	 Section 4.8
	  	Disqualification; Conflicting Interests.	  	25
			
	 Section 4.9
	  	Corporate Trustee Required; Eligibility.	  	26
			
	 Section 4.10
	  	Resignation and Removal; Appointment of Successor.	  	26
			
	 Section 4.11
	  	Acceptance of Appointment of Successor.	  	27
			
	 Section 4.12
	  	Merger, Conversion, Consolidation or Succession to Business.	  	28
			
	 Section 4.13
	  	Preferential Collection of Claims Against Company.	  	28
		
	 ARTICLE 5 HOLDERS’ LISTS AND REPORTS BY THE TRUSTEE AND COMPANY
	  	28
			
	 Section 5.1
	  	Company to Furnish Trustee Names and Addresses of Holders.	  	28
			
	 Section 5.2
	  	Preservation of Information; Communications to Holders.	  	29
			
	 Section 5.3
	  	Reports by Trustee.	  	29
			
	 Section 5.4
	  	Reports by Company.	  	29
		
	 ARTICLE 6 AMENDMENTS
	  	30
			
	 Section 6.1
	  	Amendments Without Consent of Holders.	  	30
			
	 Section 6.2
	  	Amendments with Consent of Holders.	  	31
			
	 Section 6.3
	  	Execution of Amendments.	  	31
			
	 Section 6.4
	  	Effect of Amendments; Notice to Holders.	  	32
			
	 Section 6.5
	  	Conformity with Trust Indenture Act.	  	32
			
	 Section 6.6
	  	Reference in Securities to Amendments.	  	32
		
	 ARTICLE 7 COVENANTS
	  	32
			
	 Section 7.1
	  	Payment of Amounts, if any, to Holders.	  	32
			
	 Section 7.2
	  	Maintenance of Office or Agency.	  	33
			
	 Section 7.3
	  	Money for Security Payments to Be Held in Trust.	  	33
			
	 Section 7.4
	  	Certain Purchases and Sales.	  	34

  

 ii 

					
	 Section 7.5
	  	Books and Records.	  	34
			
	 Section 7.6
	  	Audits.	  	34
			
	 Section 7.7
	  	Listing of CVRs.	  	35
			
	 Section 7.8
	  	Conflicting Arrangements.	  	36
			
	 Section 7.9
	  	Product Transfer.	  	36
			
	 Section 7.10
	  	Milestones.	  	36
			
	 Section 7.11
	  	Product Sale and Development.	  	36
			
	 Section 7.12
	  	Notice of Default.	  	37
			
	 Section 7.13
	  	Confidentiality.	  	37
			
	 Section 7.14
	  	Non-Use of Name.	  	37
		
	 ARTICLE 8 REMEDIES OF THE TRUSTEE AND HOLDERS ON EVENT OF DEFAULT
	  	38
			
	 Section 8.1
	  	Event of Default Defined; Waiver of Default.	  	38
			
	 Section 8.2
	  	Collection by the Trustee; the Trustee May Prove Payment Obligations.	  	39
			
	 Section 8.3
	  	Application of Proceeds.	  	41
			
	 Section 8.4
	  	Suits for Enforcement.	  	41
			
	 Section 8.5
	  	Restoration of Rights on Abandonment of Proceedings.	  	41
			
	 Section 8.6
	  	Limitations on Suits by Holders.	  	41
			
	 Section 8.7
	  	Unconditional Right of Holders to Institute Certain Suits.	  	42
			
	 Section 8.8
	  	Powers and Remedies Cumulative; Delay or Omission Not Waiver of Default.	  	42
			
	 Section 8.9
	  	Control by Holders.	  	42
			
	 Section 8.10
	  	Waiver of Past Defaults.	  	43
			
	 Section 8.11
	  	The Trustee to Give Notice of Default, But May Withhold in Certain Circumstances.	  	43
			
	 Section 8.12
	  	Right of Court to Require Filing of Undertaking to Pay Costs.	  	43
		
	 ARTICLE 9 CONSOLIDATION, MERGER, SALE OR CONVEYANCE
	  	44
			
	 Section 9.1
	  	Company May Consolidate, etc., on Certain Terms.	  	44
			
	 Section 9.2
	  	Successor Person Substituted.	  	44
			
	 Section 9.3
	  	Opinion of Counsel to the Trustee.	  	45
			
	 Section 9.4
	  	Successors.	  	45
		
	 ARTICLE 10 SUBORDINATION
	  	45
			
	 Section 10.1
	  	Agreement to Subordinate.	  	45

  

 iii 

					
	 Section 10.2
	  	Liquidation; Dissolution; Bankruptcy.	  	45
			
	 Section 10.3
	  	Default on Senior Obligations.	  	46
			
	 Section 10.4
	  	When Distribution Must Be Paid Over.	  	46
			
	 Section 10.5
	  	Notice by Company.	  	47
			
	 Section 10.6
	  	Subordination Effective Notwithstanding Deficiencies with Respect to Senior Obligations; Waiver of Right to Contest Senior Obligation; Reinstatement of Subordination
Provisions.	  	47
			
	 Section 10.7
	  	Subrogation.	  	48
			
	 Section 10.8
	  	Relative Rights.	  	48
			
	 Section 10.9
	  	Subordination May Not Be Impaired by Company.	  	48
			
	 Section 10.10
	  	Distribution or Notice to Representative.	  	48
			
	 Section 10.11
	  	Rights of the Trustee.	  	49
			
	 Section 10.12
	  	Authorization to Effect Subordination.	  	49
			
	 Section 10.13
	  	Amendments.	  	49
		
	ARTICLE 11 REDEMPTION OF SECURITIES	  	49
			
	 Section 11.1
	  	Notice to Trustee.	  	49
			
	 Section 11.2
	  	Selection of Securities to be Redeemed.	  	49
			
	 Section 11.3
	  	Notice of Redemption.	  	50
			
	 Section 11.4
	  	Effect of Notice of Redemption.	  	50
			
	 Section 11.5
	  	Deposit of Redemption Price.	  	50
			
	 Section 11.6
	  	Optional Redemption by the Company.	  	51

  

 
  

			
	Annex A -	  	Form of CVR Certificate.
		
	Note:	  	This table of contents shall not, for any purpose, be deemed to be a part of this CVR Agreement.

 

 iv 

 Reconciliation and tie between Trust Indenture Act of 1939 and Contingent Value Rights Agreement,
dated as of [—], 2010. [to be updated] 
  

					
	 Trust Indenture Act Section
	  	Agreement Section
			
	 Section 310
	  	(a)(1)	  	4.9
		  	(a)(2)	  	4.9
		  	(a)(3)	  	Not Applicable
		  	(a)(4)	  	Not Applicable
		  	(a)(5)	  	4.9
		  	(b)	  	4.8, 4.10
			
	 Section 311
	  	(a)	  	4.13(a)
		  	(b)	  	4.13(a)
			
	 Section 312
	  	(a)	  	5.1, 5.2(a)
		  	(b)	  	5.2(b)
		  	(c)	  	5.2(c)
			
	 Section 313
	  	(a)	  	5.3(a)
		  	(b)	  	5.3(a)
		  	(c)	  	5.3(a)
		  	(d)	  	5.3(b)
			
	 Section 314
	  	(a)	  	5.4
		  	(b)	  	Not Applicable
		  	(c)(1)	  	1.2(a)
		  	(c)(2)	  	1.2(a)
		  	(c)(3)	  	Not Applicable
		  	(d)	  	Not Applicable
		  	(e)	  	1.2(b)
			
	 Section 315
	  	(a)	  	4.1(a), 4.1(b)
		  	(b)	  	8.11
		  	(c)	  	4.1(a)
		  	(d)	  	4.1(c)
		  	(d)(1)	  	4.1(a), 4.1(b)
		  	(d)(2)	  	4.1(c)(ii)
		  	(d)(3)	  	4.1(c)(iii)
		  	(e)	  	8.12
			
	 Section 316
	  	(a)(last sentence)	  	1.15
		  	(a)(1)(A)	  	8.9
		  	(a)(1)(B)	  	8.10
		  	(a)(2)	  	Not Applicable
		  	(b)	  	8.7
			
	 Section 317
	  	(a)(1)	  	8.2
		  	(a)(2)	  	8.2
		  	(b)	  	7.3
			
	 Section 318
	  	(a)	  	1.7

  

 
 Note: This reconciliation and tie
shall not, for any purpose, be deemed to be a part of this CVR Agreement. 
  

 v 

 THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of
[—], 2010 (this “CVR Agreement”), by and between Celgene Corporation, a Delaware corporation (the “Company”), and
[—], a national banking association, as trustee (the “Trustee”), in favor of each person who from time to time holds one or more Contingent Value Rights (the
“Securities” or “CVRs”) to receive cash payments in the amounts and subject to the terms and conditions set forth herein. 

W I T N E S S E T H: 

WHEREAS, this CVR Agreement is entered into pursuant to the Agreement and Plan of Merger, dated as of June 30, 2010
(as amended prior to the effective time thereof, the “Merger Agreement”), by and among the Company, Artistry Acquisition Corp., a Delaware corporation and wholly owned Subsidiary of the Company (“Sub”), and Abraxis
BioScience, Inc., a Delaware corporation (“Abraxis”); 
 WHEREAS, pursuant to the Merger
Agreement, Sub will merge with and into Abraxis (the “Merger”), with Abraxis being the surviving corporation in the Merger and becoming a wholly-owned Subsidiary of the Company; 

WHEREAS, in the Merger, one (1) CVR will be issued in respect of (a) each share of common stock, par value
$0.001 per share, of Abraxis (“Common Stock”) (other than shares of Common Stock that are Excluded Company Shares or Dissenting Company Shares) (all as defined in the Merger Agreement), (b) each share of Common Stock underlying
each Option (as defined in the Merger Agreement) having an exercise price that is less than or equal to the Per Share Amount (as defined in the Merger Agreement), (c) each share of Common Stock underlying each Option having an exercise price
that is greater than the Per Share Amount, if such Option is exercised and settled in accordance with the Merger Agreement, (d) each SAR (as defined in the Merger Agreement) having a base appreciation amount that is less than or equal to the
Per Share Amount, (e) each SAR having a base appreciation amount that is greater than the Per Share Amount, if such SAR is exercised and settled in accordance with the Merger Agreement, and (f) each RSU (as defined in the Merger
Agreement), in each case, outstanding immediately prior to the Effective Time (as defined in the Merger Agreement); and 

WHEREAS, a registration statement on Form S-4 (No. 333-[—]) (the
“Registration Statement”) with respect to the CVRs has been prepared and filed by the Company with the Commission (as defined below) and has become effective in accordance with the Securities Act of 1933, as amended (the
“Securities Act”). 
 NOW, THEREFORE, in consideration of the foregoing premises and the
consummation of the transactions contemplated by the Merger Agreement, it is covenanted and agreed, for the equal and proportionate benefit of all Holders of the Securities, as follows: 

ARTICLE 1 

DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 

Section 1.1 Definitions. For all purposes of this CVR Agreement, except as otherwise expressly provided or unless
the context otherwise requires: 
  

 1 

 (a) the terms defined in this Article have the meanings assigned to them in
this Article, and include the plural as well as the singular; 
 (b) all accounting terms used herein and not
expressly defined herein shall, except as otherwise noted, have the meanings assigned to such terms in accordance with applicable Accounting Standards, where “Accounting Standards” means (A) GAAP (United States Generally
Accepted Accounting Principles); or (B) to the extent that the Company adopts International Financial Reporting Standards (IFRS), then “Accounting Standards” means International Financial Reporting Standards (IFRS), in either
case consistently applied; 
 (c) all capitalized terms used in this CVR Agreement without definition shall have
the respective meanings ascribed to them in the Merger Agreement; 
 (d) all other terms used herein which are
defined in the Trust Indenture Act (as defined herein), either directly or by reference therein, have the respective meanings assigned to them therein; and 

(e) the words “herein,” “hereof” and “hereunder” and other words of
similar import refer to this CVR Agreement as a whole and not to any particular Article, Section or other subdivision. 

“Affiliate” of any specified Person means any other Person directly or indirectly controlling or
controlled by or under direct or indirect common control with such specified Person. For the purposes of this definition, “control” when used with respect to any specified Person means the power to direct the management and policies of
such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise; and the terms “controlling” and “controlled” have meanings correlative to the foregoing. 

“Board of Directors” means the board of directors of the Company or any other body performing similar
functions, or any duly authorized committee of that board. 
 “Board Resolution” means a copy
of a resolution certified by the Secretary or an Assistant Secretary of the Company, to have been duly adopted by the Board of Directors and to be in full force and effect on the date of such certification, and delivered to the Trustee. 

“Business Day” means any day (other than a Saturday or a Sunday) on which banking institutions in The
City of New York, New York are not authorized or obligated by Law or executive order to close and, if the CVRs are listed on a national securities exchange, electronic trading network or other suitable trading platform, such exchange, electronic
network or other trading platform is open for trading. 
 “Call Notice” shall have the meaning
set forth in Section 11.3 of this CVR Agreement. 
 “Combination Product” means any
product that comprises a Product sold in conjunction with another active component (whether packaged together or in the same therapeutic formulation or otherwise) or service. 

 

 2 

 “Commission” means the Securities and Exchange Commission,
as from time to time constituted, created under the Exchange Act (as defined herein), or if at any time after the execution of this instrument such Commission is not existing and performing the duties now assigned to it under the Trust Indenture
Act, then the body performing such duties at such time. 
 “Common Stock” shall have the
meaning set forth in the Recitals of this CVR Agreement. 
 “Company” means the Person (as
defined herein) named as the “Company” in the first paragraph of this CVR Agreement, until a successor Person shall have become such pursuant to the applicable provisions of this CVR Agreement, and thereafter “Company” shall mean
such successor Person. To the extent necessary to comply with the requirements of the provisions of Trust Indenture Act Sections 310 through 317, inclusive, to the extent that they are applicable to the Company, the term “Company” shall
include any other obligor with respect to the Securities for the purposes of complying with such provisions. 

“Company Request” or “Company Order” means a written request or order signed in the
name of the Company by the chairman of the Board of Directors or the president or any vice president, the controller or assistant controller and the treasurer or assistant treasurer or the secretary or any assistant secretary, and delivered to the
Trustee. 
 “Confidential Information” shall have the meaning set forth in Section 7.13 of
this CVR Agreement. 
 “Consent and Purchase Offer” shall have the meaning set forth in
Section 11.1 of this CVR Agreement. 
 “Corporate Trust Office” means the office of the
Trustee at which at any particular time its corporate trust business shall be principally administered, which office at the date of execution of this CVR Agreement is located at [—]. 

“CVRs” shall have the meaning set forth in the Preamble of this CVR Agreement. 

“CVR Agreement” means this instrument as originally executed and as it may from time to time be
supplemented or amended pursuant to the applicable provisions hereof. 
 “CVR Certificate”
means a certificate representing any of the CVRs. 
 “CVR Payment” means any Net Sales Payment
and any Milestone Payment. 
 “CVR Shortfall” shall have the meaning set forth in
Section 7.6(b) of this CVR Agreement. 
 “Default Interest Rate” means a rate equal to the
sum of three percent (3%) plus the prime rate of interest quoted in the Money Rates section of The Wall Street Journal (New York Edition), or similar reputable data source, calculated daily on the basis of a three hundred sixty-five
(365) day year or, if lower, the highest rate permitted under applicable Law. 
  

 3 

 “Diligent Efforts” means, with respect to any Product,
efforts of a Person to carry out its obligations in a diligent manner using such effort and employing such resources normally used by such Person in the exercise of its reasonable business discretion relating to the research, development or
commercialization of a product, that is of similar market potential at a similar stage in its development or product life, taking into account issues of market exclusivity (including patent coverage, regulatory and other exclusivity), safety and
efficacy, product profile, the competitiveness of alternate products in the marketplace or under development, the launch or sales of a generic or biosimilar product, the regulatory structure involved, and the profitability of the applicable product
(including pricing and reimbursement status achieved), and other relevant factors, including technical, commercial, legal, scientific, and/or medical factors. 

“Existing Licenses” means those licenses and related agreements (for so long as they are in effect) with
respect to the Products granted by the Company or its Affiliates to third parties (other than the Company or its Affiliates) as in effect immediately prior to the consummation of the Merger (with such modifications thereto after the consummation of
the Merger that do not reduce the amounts of royalties, milestone payments or profit split payments thereunder). 

“Event of Default” shall have the meaning set forth in Section 8.1 of this CVR Agreement.

 “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

“Exchange Act Documents” shall have the meaning set forth in Section 5.4 of this CVR Agreement.

 “FDA” means the United States Food and Drug Administration or any successor agency.

 “Governmental Entity” means any domestic (federal or state), or foreign court, commission,
governmental body, regulatory or administrative agency or other political subdivision thereof. 

“Holder” means a Person in whose name a Security is registered in the Security Register. 

“Independent Accountant” shall have the meaning set forth in Section 7.6(a) of this CVR Agreement. 

“Indications” means U.S. Regulatory Approval of the Product described in clause (a) of the
definition of “Product” for use in the treatment of: (i) melanoma; (ii) ovarian cancer; (iii) bladder cancer; and (iv) first-line metastatic breast cancer. 

“Junior Obligations” has the meaning set forth in Section 10.1. 

“Law” means any foreign, federal, state, local or municipal laws, rules, judgments orders, regulations,
statutes, ordinances, codes, decisions, injunctions, orders, decrees or requirements of any Governmental Entity. 
  

 4 

 “Majority Holders” means, at the time of determination,
Holders of at least a majority of the Outstanding CVRs. 
 “Merger” shall have the meaning set
forth in the Recitals of this CVR Agreement. 
 “Merger Agreement” shall have the meaning set
forth in the Recitals of this CVR Agreement. 
 “Milestone” means each of (i) Milestone
#1, and (ii) Milestone #2. 
 “Milestone #1” means U.S. Regulatory Approval of the Product
described in clause (a) of the definition of “Product” for use in the treatment of non-small cell lung cancer (NSCLC), which U.S. Regulatory Approval permits the Company to market such Product under a label that includes a progression
free survival claim, but only if the foregoing milestone is achieved no later than the Milestone Target Date. For the avoidance of doubt, an “approvable letter” or similar communication published by the FDA shall not constitute approval
for purposes of the foregoing. 
 “Milestone #2” means U.S. Regulatory Approval of the Product
described in clause (a) of the definition of “Product” for use in the treatment of pancreatic cancer, which U.S. Regulatory Approval permits the Company to market such Product under a label that includes an overall survival claim, but
only if the foregoing milestone is achieved no later than the Milestone Target Date. For the avoidance of doubt, an “approvable letter” or similar communication published by the FDA shall not constitute approval for purposes of the
foregoing. 
 “Milestone Payment” means, as applicable, (i) two hundred fifty million
dollars ($250,000,000), with respect to the achievement of Milestone #1; and (ii) (a) four hundred million dollars ($400,000,000), with respect to the achievement of Milestone #2 if Milestone #2 is achieved no later than April 1,
2013, and (b) three hundred million dollars ($300,000,000), with respect to the achievement of Milestone #2 if Milestone #2 is achieved after April 1, 2013 but no later than the Milestone Target Date. 

“Milestone Payment Date” means, with respect to each Milestone, the date that is twenty
(20) Business Days following the date of the achievement of such Milestone. 
 “Milestone Target
Date” means the fifth anniversary of the date of this CVR Agreement. 
 “Net Sales”
means, for each Net Sales Measuring Period, the sum of, without any duplication: (i) the gross amounts invoiced for the Products sold by the Company, its Affiliates or its licensees (other than licensees under Existing Licenses) to third
parties (other than the Company, its Affiliates or its licensees) during such Net Sales Measuring Period, including wholesale distributors, less deductions from such amounts calculated in accordance with Accounting Standards so as to arrive at
“net sales” under Accounting Standards as reported by the Company, its Affiliate or its licensee, as applicable, in such Person’s financial statements, and further reduced by write-offs of accounts receivables or increased for
collection of accounts that were previously written off; plus (ii) (A) the amount of royalties and profit split payments received by the Company or its Affiliates from their respective licensees under Existing Licenses

  

 5 

 
for sales (but not the supply) of Products sold by such licensees to third parties (other than the Company or its Affiliates) during such Net Sales Measuring Period, and (B) the amount of
any milestone payments received during such Net Sales Measuring Period by the Company or its Affiliates from their licensees under Existing Licenses with respect to the Products. 

Any and all set-offs against gross invoice prices shall be calculated in accordance with Accounting Standards. Sales or
other commercial dispositions of a Product between the Company and its Affiliates and its licensees shall be excluded from the computation of Net Sales; Product provided to third parties without charge, in connection with research and development,
clinical trials, compassionate use, humanitarian and charitable donations, or indigent programs or for use as samples shall be excluded from the computation of Net Sales; and no payments will be payable on such sales or such other commercial
dispositions, except where such an Affiliate or licensee is an end user of the Product. 
 Notwithstanding the
foregoing, if a Product is sold or otherwise commercially disposed of for consideration other than cash or in a transaction that is not at arm’s length between the buyer and the seller, then the gross amount to be included in the calculation of
Net Sales shall be the amount that would have been invoiced had the transaction been conducted at arm’s length and for cash. Such amount that would have been invoiced shall be determined, wherever possible, by reference to the average selling
price of such Product in arm’s length transactions in the relevant country. 
 Notwithstanding the
foregoing, in the event a Product is sold as a Combination Product in a particular country, Net Sales shall be calculated by multiplying the Net Sales of the Combination Product by the fraction A/(A+B), where A is the gross invoice price of the
Product if sold separately in a country and B is the gross invoice price of the other product(s) included in the Combination Product if sold separately in such country. If no such separate sales are made by the Company, its Affiliates or licensees
in a country, Net Sales of the Combination Product shall be calculated in a manner determined by the Company in good faith based upon the relative value of the active components of such Combination Product. 

“Net Sales Measuring Period” means the one-year period beginning
January 1st of each year during the term of this CVR
Agreement and ending December 31st of each year
during the term of this CVR Agreement; provided that the first Net Sales Measuring Period will begin on January 1, 2011 and end on December 31, 2011. 

“Net Sales Payment” means, with respect to any Net Sales Measuring Period, an amount equal to
(i) two and one-half percent (2.5%) of that portion of Net Sales of the Products that exceeds one billion dollars ($1,000,000,000) but is less than or equal to two billion dollars ($2,000,000,000) for such period, plus (ii) an
additional amount equal to five percent (5.0%) of that portion of Net Sales of the Products that exceeds two billion dollars ($2,000,000,000) but is less than or equal to three billion dollars ($3,000,000,000) for such period, plus
(iii) an additional amount equal to ten percent (10.0%) of that portion of Net Sales of the Products that exceeds three billion dollars ($3,000,000,000) for such period; provided that no Net Sales Payments will be due following a Net Sales
Payment Termination Date. 
  

 6 

 “Net Sales Payment Dates” means the
fifteenth (15th) day after the date the Company is
required to provide the Net Sales Statement pursuant to Section 5.4 for the Net Sales Measuring Period in respect of which a Net Sales Payment is due. 

“Net Sales Payment Termination Date” means the last day of the Net Sales Measuring Period ending on
December 31, 2025; provided that, if Net Sales of the Products for the Net Sales Measuring Period ending on December 31, 2025 are equal to or greater than one billion dollars ($1,000,000,000), then the Net Sales Payment Termination Date
shall be extended until the earlier of (a) the last day of the first Net Sales Measuring Period subsequent to December 31, 2025 during which Net Sales of the Products are less than one billion dollars ($1,000,000,000) and
(b) December 31, 2030. 
 “Net Sales Statement” means, with respect to each Net Sales
Measuring Period, the written statement of the Company, certified by the Chief Financial Officer of the Company and setting forth with reasonable detail (i)(a), for the Products for all countries in the aggregate, (X) the total of the gross
invoice price charged by the Company, its Affiliates and its licensees (other than licensees under Existing Licenses) for sales of the Products by the Company, its Affiliates and their respective licensees (other than licensees under Existing
Licenses) to third parties (other than the Company or its Affiliates) during the applicable period, (Y) an itemized calculation of Net Sales for the Products showing deductions for such Net Sales Measuring Period provided for in accordance with
the definition of Net Sales, and (Z)(1) the total of all royalties and profit split payments received by the Company and its Affiliates from their respective licensees under Existing Licenses for sales of the Products by their respective licensees
during the applicable period, and (2) the amount of any milestone payments received during such Net Sales Measuring Period by the Company or its Affiliates from their licensees under Existing Licenses with respect to the Products, (b) to
the extent that Net Sales for the Products for an applicable period is determined based on Net Sales of a Combination Product for such period, the method of determining the Net Sales of the Combination Product attributable to the Products in
accordance with the definition of Net Sales, and (c) to the extent that sales for the Products for an applicable period is recorded in currencies other than United States dollars, the exchange rates used for conversion of such foreign currency
into United States dollars and (ii) the calculation of the Net Sales Payment due, if any, in respect of the applicable Net Sales Measuring Period in accordance with this CVR Agreement. 

“Officer’s Certificate” when used with respect to the Company means a certificate signed by the
chairman of the Board of Directors or the president or any vice president, the controller or assistant controller and the treasurer or assistant treasurer or the secretary or any assistant secretary of the Company delivered to the Trustee or any
other person authorized to act on behalf of the Company. 
 “Opinion of Counsel” means a
written opinion of counsel, who may be counsel for the Company. 
 “Outstanding” when used with
respect to Securities means, as of the date of determination, all Securities theretofore authenticated and delivered under this CVR Agreement, except: (i) Securities theretofore cancelled by the Trustee or delivered to the Trustee for
cancellation and (ii) Securities in exchange for or in lieu of which other Securities have been 
  

 7 

 
authenticated and delivered pursuant to this CVR Agreement, other than any such Securities in respect of which there shall have been presented to the Trustee proof satisfactory to it that such
Securities are held by a bona fide purchaser in whose hands the Securities are valid obligations of the Company; provided, however, that in determining whether the Holders of the requisite Outstanding Securities have given any request, demand,
direction, consent or waiver hereunder, Securities owned by the Company or any Affiliate of the Company, whether held as treasury securities or otherwise, shall be disregarded and deemed not to be Outstanding. 

“Party” shall mean the Trustee, the Company and/or Holder(s), as applicable. 

“Paying Agent” means any Person authorized by the Company to pay the amount determined pursuant to
Section 3.1, if any, on any Securities on behalf of the Company. 
 “Payment Date” means
any Net Sales Payment Date, any Milestone Payment Date, and any such date as shall be required for any CVR Shortfall payment pursuant to the review procedure set forth in Section 7.6. 

“Person” means any individual, corporation, partnership, joint venture, association, joint-stock
company, trust, limited liability company, unincorporated organization or government or any agency or political subdivision thereof. 

“Products” means each of: 

(a) the pharmaceutical product comprising the chemical compound having the chemical name of
5ß,20-Epoxy-1,2a,4,7ß,10ß,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine (with the structure below), known by the generic name “paclitaxel” and bound to albumin
that is the subject of the New Drug Application No. 21-660 filed with the FDA and subject of the European Medicines Agency Marketing Authorization granted on January 11, 2008, together with all amendments and supplements to such FDA and
European Medicines Agency approvals (identified by the Company as ABRAXANE); provided that in all cases such Product is an injectable formulation.

 

 

  

 8 

 (b) the pharmaceutical product comprising the chemical compound having the
chemical name of (2R,3S)-N-carboxy-3-phenylisoserine,N-tert-butyl ester, 13-ester with 5ß-20-epoxy-1,2 ,4,7ß,10ß,13 -hexahydroxytax-11-en-9-one 4-acetate 2-benzoate, anhydrous(with the structure below) bound to albumin that
is the subject of the Investigational New Drug Application No. 73,527 filed with the FDA together with all amendments (identified by the Company as “nab-docetaxel (ABI-008)”); provided that in all cases such Product is an injectable
formulation. 
 (c) the pharmaceutical product comprising the chemical compound having the chemical name of
(3S, 6R, 7E, 9R, 10R, 12R, 14S, 15E, 17E, 19E, 21S, 23S, 26R, 27R, 34aS)-9, 10, 12, 13, 14, 21, 22, 23, 24, 25, 26, 27, 32, 33, 34,
34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S, 3R, 4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6, 8, 12, 14, 20, 26-hexamethyl-23, 27-epoxy-3H-pyrido[2, 1-c][1,4] oxaazacyclohentriacontine
-1, 5, 11, 28, 29 (4H,6H,31H)-pentone (with the structure below) bound to albumin that is the subject of the Investigational New Drug Application No. 74.610 filed with the FDA together with all amendments (identified by the Company as
“nab-rapamycin (ABI-009)”); provided that in all cases such Product is an injectable formulation.

 

 

 (d) the pharmaceutical product comprising the chemical compound having the chemical name of
17-allylamino-17-demethoxygeldanamycin, 17-allylamino geldanamycin (with the structure below) bound to albumin that is the subject of the Investigational New Drug Application No. 78,298 filed with the FDA together with all amendments
(identified by the Company as “nab-17AAG (ABI-010)”); provided that in all cases such Product is an injectable formulation. 
  

 9 

 

 

 (e) the pharmaceutical product comprising the chemical compound having the chemical name of
N-(1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9- tetrahydro-benzo[a]heptalen-7-yl)-3-[3-(1,2,3-trimethoxy-10-methylsulfanyl-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl)-ureido]-propionamide(with the structure below) bound to albumin that is
the subject of the Investigational New Drug Application No. 103,698 filed with the FDA together with all amendments (identified by the Company as “nab-thiocolchicine dimer (ABI-011)”); provided that in all cases the Product is an
injectable formulation. 

 

 

 (f) the pharmaceutical product comprising the chemical compound having the chemical name of
(aR,
ßS)-ß-[[(1,1-Dimethylethoxy)carbonyl]amino]-a-(hexanoyloxy)benzenepropanoic acid
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodecal[3,4]benz[1,2-b]oxet-9-yl
 ester (with the structure below) bound to albumin (identified by the Company as “nab-novel taxane (ABI-013)”) provided that in all cases the Product is an injectable formulation.

 

 10 

 

 

 (g) the pharmaceutical product comprising the chemical compound having the chemical name of
Benzenepropanoic acid, ß-(benzoylamino)-a-hydroxy-,6,12bbis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12bdodecahydro-
4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]-oxet-9-yl
ester,[2aR-[2aa,4ß,4aß,6ß,9a(aR*,ßS*),11a
,12a,12aa, 12ba]] bound to albumin that is the subject of the Investigational New Drug Application
No. 63,082 filed with the FDA together with all amendments (identified by the Company as “COROXANE”); provided that in all cases the Product is an injectable formulation. 

“Redemption Eligibility Date” means the date that fifty percent (50%) of the Securities issued
pursuant to the terms of the Merger Agreement either are (i) no longer Outstanding, and/or (ii) repurchased, acquired, redeemed or retired by the Company. 

“Registration Statement” shall have the meaning set forth in the Recitals of this CVR Agreement.

 “Regulatory Approval” means all approvals from the FDA or other non-U.S. regulatory
authority necessary for the commercial manufacture, marketing and sale of a product in the United States or other jurisdiction in accordance with applicable Law. 

“Representatives” shall have the meaning set forth in Section 7.13 of this CVR Agreement.

 “Responsible Officer” when used with respect to the Trustee means any officer assigned to
the Corporate Trust Office and also means, with respect to any particular corporate trust matter, any other officer of the Trustee to whom such matter is referred because of his knowledge of and familiarity with the particular subject. 

“Securities” shall have the meaning set forth in the Preamble of this CVR Agreement. 

“Securities Act” shall have the meaning set forth in the Recitals of this CVR Agreement. 

 

 11 

 “Security Register” shall have the meaning set forth in Section 3.5(a)
of this CVR Agreement. 
 “Senior Obligations” means any existing or future obligations of the Company,
including the principal of, premium (if any), interest (including, without limitation, any interest accruing subsequent to the filing of a petition of bankruptcy at the rate provided for in the documentation with respect thereto, whether or not such
interest is an allowed claim under applicable Law) on, and all other amounts owing thereon, (i) with respect to borrowed money, (ii) evidenced by notes, debentures, bonds or other similar debt instruments, (iii) with respect to the
net obligations owed under interest rate swaps or similar agreements or currency exchange transactions, (iv) reimbursement obligations in respect of letters of credit and similar obligations, (v) in respect of capital leases, or
(vi) guarantees in respect of obligations referred to in clauses (i) through (v) above; unless, in any case, the instrument creating or evidencing the same or pursuant to which the same is outstanding provides that such obligations
are pari passu to or subordinate in right of payment to the Securities. 
 Notwithstanding the foregoing,
“Senior Obligations” shall not include: 
  

	 	(a)	 Junior Obligations; 

  

	 	(b)	 trade debt incurred in the ordinary course of business; 

 

	 	(c)	 any intercompany indebtedness between the Company and any of its Subsidiaries or Affiliates; 

 

	 	(d)	 indebtedness of the Company that is subordinated in right of payment to Senior Obligations; 

 

	 	(e)	 indebtedness or other obligations of the Company that by its terms ranks equal or junior in right of payment to the Junior Obligations;

  

	 	(f)	 indebtedness of the Company that, by operation of Law, is subordinate to any general unsecured obligations of the Company; and

  

	 	(g)	 indebtedness evidenced by any guarantee of indebtedness ranking equal or junior in right of payment to the Junior Obligations.

 “Shortfall Interest Rate” means a rate equal to the sum of two percent
(2%) plus the prime rate of interest quoted in the Money Rates section of The Wall Street Journal (New York Edition), or similar reputable data source, calculated daily on the basis of a three hundred sixty-five (365) day year or,
if lower, the highest rate permitted under applicable Law. 
 “Shortfall Report” shall have the
meaning set forth in Section 7.6(b) of this CVR Agreement. 
 “Sub” shall have the meaning
set forth in the Recitals of this CVR Agreement. 
  

 12 

 “Subsidiary” means, with respect to any Person, any
corporation, limited liability company, association, partnership or other business entity of which more than fifty percent (50%) of the total voting power of shares of Voting Securities is at the time owned or controlled, directly or
indirectly, by: (i) such Person; (ii) such Person and one or more Subsidiaries of such Person; or (iii) one or more Subsidiaries of such Person. 

“Tax” means any federal, state, local or foreign income, profits, gross receipts, license, payroll,
employment, severance, stamp, occupation, premium, windfall profits, environmental, customs duty, capital stock, franchise, sales, social security, unemployment, disability, use, property, withholding, excise, transfer, registration, production,
value added, alternative minimum, occupancy, estimated or any other tax of any kind whatsoever, together with any interest, penalty or addition thereto, imposed by any Governmental Entity responsible for the imposition of any such tax, whether
disputed or not. 
 “Tax Return” means any return, report, declaration, claim or other
statement (including attached schedules) relating to Taxes. 
 “Trust Indenture Act” means the
Trust Indenture Act of 1939, as amended from time to time. 
 “Trustee” means the Person named
as the “Trustee” in the first paragraph of this CVR Agreement, until a successor Trustee shall have become such pursuant to the applicable provisions of this CVR Agreement, and thereafter “Trustee” shall mean such successor
Trustee. 
 “Vice President” when used with respect to the Company or the Trustee, means any
vice president, whether or not designated by a number or a word or words added before or after the title of “vice president.” 

“Voting Securities” means securities or other interests having voting power, or the right, to elect or
appoint a majority of the directors, or any Persons performing similar functions, irrespective of whether or not stock or other interests of any other class or classes shall have or might have voting power or any right by reason of the happening of
any contingency. 
 Section 1.2 Compliance and Opinions. 

(a) Upon any application or request by the Company to the Trustee to take any action under any provision of this CVR
Agreement, the Company shall furnish to the Trustee an Officers’ Certificate stating that, in the opinion of the signor, all conditions precedent, if any, provided for in this CVR Agreement relating to the proposed action have been complied
with and an Opinion of Counsel stating, subject to customary exceptions, that in the opinion of such counsel all such conditions precedent, if any, have been complied with, except that, in the case of any such application or request as to which the
furnishing of such documents is specifically required by any provision of this CVR Agreement relating to such particular application or request, no additional certificate or opinion need be furnished. 

(b) Every certificate or opinion with respect to compliance with a condition or covenant provided for in this CVR
Agreement shall include: (i) a statement that each individual signing such certificate or opinion has read such covenant or condition and the definitions herein 

 

 13 

 
relating thereto; (ii) a brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions contained in such certificate or opinion are
based; (iii) a statement that, in the opinion of each such individual, he or she has made such examination or investigation as is necessary to enable him to express an informed opinion as to whether or not such covenant or condition has been
complied with; and (iv) a statement as to whether, in the opinion of each such individual, such condition or covenant has been complied with. 

Section 1.3 Form of Documents Delivered to Trustee. 

(a) In any case where several matters are required to be certified by, or covered by an opinion of, any specified Person,
it is not necessary that all such matters be certified by, or covered by the opinion of, only one such Person, or that they be so certified or covered by only one document, but one such Person may certify or give an opinion with respect to some
matters and one or more other such Persons as to other matters, and any such Person may certify or give an opinion as to such matters in one or several documents. 

(b) Any certificate or opinion of an officer of the Company may be based, insofar as it relates to legal matters, upon a
certificate or opinion of, or representations by, counsel. Any such certificate or Opinion of Counsel may be based, insofar as it relates to factual matters, upon a certificate or opinion of, or representations by, an officer or officers of the
Company stating that the information with respect to such factual matters is in the possession of the Company. 

(c) Any certificate, statement or opinion of an officer of the Company or of counsel may be based, insofar as it relates
to accounting matters, upon a certificate or opinion of or representations by an accountant or firm of accountants in the employ of the Company. Any certificate or opinion of any independent firm of public accountants filed with the Trustee shall
contain a statement that such firm is independent. 
 (d) Where any Person is required to make, give or execute
two or more applications, requests, consents, certificates, statements, opinions or other instruments under this CVR Agreement, they may, but need not, be consolidated and form one instrument. 

Section 1.4 Acts of Holders. 

(a) Any request, demand, authorization, direction, notice, consent, waiver or other action provided by this CVR Agreement
to be given or taken by Holders may be embodied in and evidenced by one or more instruments of substantially similar tenor signed by such Holders in person or by an agent duly appointed in writing; and, except as herein otherwise expressly provided,
such action shall become effective when such instrument or instruments are delivered to the Trustee and, where it is hereby expressly required, to the Company. Such instrument or instruments (and the action embodied therein and evidenced thereby)
are herein sometimes referred to as the “Act” of the Holders signing such instrument or instruments. Proof of execution of any such instrument or of a writing appointing any such agent shall be sufficient for any purpose of this CVR
Agreement and (subject to Section 4.1) conclusive in favor of the Trustee and the Company, if made in the manner provided in this Section. The Company may 

 

 14 

 
set a record date for purposes of determining the identity of Holders entitled to vote or consent to any action by vote or consent authorized or permitted under this CVR Agreement. If not
previously set by the Company, (i) the record date for determining the Holders entitled to vote at a meeting of the Holders shall be the date preceding the date notice of such meeting is mailed to the Holders, or if notice is not given, on the
day next preceding the day such meeting is held, and (ii) the record date for determining the Holders entitled to consent to any action in writing without a meeting shall be the first date on which a signed written consent setting forth the
action taken or proposed to be taken is delivered to the Company. If a record date is fixed, those Persons who were Holders of Securities at such record date (or their duly designated proxies), and only those Persons, shall be entitled to take such
action by vote or consent or, except with respect to clause (d) below, to revoke any vote or consent previously given, whether or not such Persons continue to be Holders after such record date. No such vote or consent shall be valid or
effective for more than one hundred twenty (120) days after such record date. 
 (b) The fact and date of
the execution by any Person of any such instrument or writing may be proved in any reasonable manner which the Trustee deems sufficient. 

(c) The ownership of Securities shall be proved by the Security Register. Neither the Company nor the Trustee nor any
Agent of the Company or the Trustee shall be affected by any notice to the contrary. 
 (d) At any time prior to
(but not after) the evidencing to the Trustee, as provided in this Section 1.4, of the taking of any action by the Holders of the Securities specified in this CVR Agreement in connection with such action, any Holder of a Security the serial
number of which is shown by the evidence to be included among the serial numbers of the Securities the Holders of which have consented to such action may, by filing written notice at the Corporate Trust Office and upon proof of holding as provided
in this Section 1.4, revoke such action so far as concerns such Security. Any request, demand, authorization, direction, notice, consent, waiver or other action by the Holder of any Security shall bind every future Holder of the same Security
or the Holder of every Security issued upon the registration of transfer thereof or in exchange therefor or in lieu thereof, in respect of anything done, suffered or omitted to be done by the Trustee, any Paying Agent or the Company in reliance
thereon, whether or not notation of such action is made upon such Security. 
 Section 1.5 Notices,
etc., to Trustee and Company. Any request, demand, authorization, direction, notice, consent, waiver or Act of Holders or other document provided or permitted by this CVR Agreement to be made upon, given or furnished to, or filed with:

 (a) the Trustee by any Holder or by the Company shall be sufficient for every purpose hereunder if made,
given, furnished or filed, in writing, to or with the Trustee at its Corporate Trust Office; or 
 (b) the
Company by the Trustee or by any Holder shall be sufficient for every purpose hereunder if in writing and mailed, first-class postage prepaid, to the Company addressed to it at Celgene Corporation, 86 Morris Avenue, Summit, New Jersey 07901, Legal
Department, Attention: Senior Vice President and Chief Counsel, or at any other address previously furnished in writing to the Trustee by the Company. 
  

 15 

 Section 1.6 Notice to Holders; Waiver. 

(a) Where this CVR Agreement provides for notice to Holders of any event, such notice shall be sufficiently given (unless
otherwise herein expressly provided) if in writing and mailed, first-class postage prepaid, to each Holder affected by such event, at his address as it appears in the Security Register, not later than the latest date, and not earlier than the
earliest date, prescribed for the giving of such notice. In any case where notice to Holders is given by mail, neither the failure to mail such notice, nor any defect in any notice so mailed, to any particular Holder shall affect the sufficiency of
such notice with respect to other Holders. Where this CVR Agreement provides for notice in any manner, such notice may be waived in writing by the Person entitled to receive such notice, either before or after the event, and such waiver shall be the
equivalent of such notice. Waivers of notice by Holders shall be filed with the Trustee, but such filing shall not be a condition precedent to the validity of any action taken in reliance upon such waiver. 

(b) In case by reason of the suspension of regular mail service or by reason of any other cause, it shall be
impracticable to mail notice of any event as required by any provision of this CVR Agreement, then any method of giving such notice as shall be satisfactory to the Trustee shall be deemed to be a sufficient giving of such notice. 

Section 1.7 Conflict with Trust Indenture Act. If any provision hereof limits, qualifies or conflicts with
another provision hereof which is required to be included in this CVR Agreement by any of the provisions of the Trust Indenture Act, such required provision shall control. 

Section 1.8 Effect of Headings and Table of Contents. The Article and Section headings herein and the Table
of Contents are for convenience only and shall not affect the construction hereof. 
 Section 1.9
Benefits of Agreement. Nothing in this CVR Agreement or in the Securities, express or implied, shall give to any Person (other than the Parties hereto and their successors hereunder, any Paying Agent and the Holders) any benefit or any legal
or equitable right, remedy or claim under this CVR Agreement or under any covenant or provision herein contained, all such covenants and provisions being for sole benefit of the Parties hereto and their successors, any Paying Agent and of the
Holders. 
 Section 1.10 Governing Law. THIS CVR AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK INCLUDING, WITHOUT LIMITATION, SECTIONS 5-1401 AND 5-1402 OF THE NEW YORK GENERAL OBLIGATIONS LAW WITHOUT REGARD TO THE CONFLICT OF LAWS PRINCIPLES THEREOF. EACH OF THE COMPANY, THE TRUSTEE AND EACH
OF THE HOLDERS BY THEIR ACCEPTANCE OF THE SECURITIES, HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF ANY NEW YORK STATE COURT SITTING IN THE BOROUGH OF MANHATTAN IN THE CITY OF NEW YORK OR ANY FEDERAL COURT SITTING IN THE BOROUGH OF
MANHATTAN IN THE CITY OF NEW YORK IN RESPECT OF ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS CVR AGREEMENT AND THE 

 

 16 

 
SECURITIES, AND IRREVOCABLY ACCEPTS FOR ITSELF AND IN RESPECT OF ITS PROPERTY, GENERALLY AND UNCONDITIONALLY, JURISDICTION OF THE AFORESAID COURTS. EACH OF THE COMPANY AND THE TRUSTEE AGREES THAT
PROCESS MAY BE SERVED UPON THEM IN ANY MANNER AUTHORIZED BY THE LAWS OF THE STATE OF NEW YORK FOR SUCH PERSONS AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT IT MAY EFFECTIVELY DO SO UNDER APPLICABLE LAW, ANY OBJECTION IT MAY NOW OR HEREAFTER HAVE TO
SUCH SERVICE OF PROCESS, THE LAYING OF THE VENUE OF ANY SUCH SUIT, ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT AND ANY CLAIM THAT ANY SUCH SUIT, ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. 

Section 1.11 Legal Holidays. In the event that a Payment Date shall not be a Business Day, then
(notwithstanding any provision of this CVR Agreement or the Securities to the contrary) payment on the Securities need not be made on such date, but may be made, without the accrual of any interest thereon, on the next succeeding Business Day with
the same force and effect as if made on such Payment Date. 
 Section 1.12 Separability Clause. In
case any provision in this CVR Agreement or in the CVRs shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 

Section 1.13 No Recourse Against Others. A director, officer or employee, as such, of the Company or the
Trustee shall not have any liability for any obligations of the Company or the Trustee under the Securities or this CVR Agreement or for any claim based on, in respect of or by reason of such obligations or their creation. By accepting a Security
each Holder waives and releases all such liability. The waiver and release are part of the consideration for the issue of the Securities. 

Section 1.14 Counterparts. This CVR Agreement shall be signed in any number of counterparts with the same
effect as if the signatures to each counterpart were upon a single instrument, and all such counterparts together shall be deemed an original of this CVR Agreement. 

Section 1.15 Acceptance of Trust. [—], the Trustee named
herein, hereby accepts the trusts in this CVR Agreement declared and provided, upon the terms and conditions set forth herein. 

ARTICLE 2 

SECURITY FORMS 

Section 2.1 Forms Generally. 

(a) The Securities and the Trustee’s certificate of authentication shall be in substantially the forms set forth in
Annex A, attached hereto and incorporated herein by this reference, with such appropriate insertions, omissions, substitutions and other variations as are required or permitted by this CVR Agreement and may have such letters, numbers or other

  

 17 

 
marks of identification and such legends or endorsements placed thereon as may be required to comply with the rules of any securities exchange or as may be required by Law or any rule or
regulation pursuant thereto, all as may be determined by the officers executing such Securities, as evidenced by their execution of the Securities. Any portion of the text of any Security may be set forth on the reverse thereof, with an appropriate
reference thereto on the face of the Security. 
 (b) The definitive Securities shall be typewritten, printed,
lithographed or engraved on steel engraved borders or produced by any combination of these methods or may be produced in any other manner permitted by the rules of any securities exchange on which the Securities may be listed, all as determined by
the officers executing such Securities, as evidenced by their execution of such Securities. 
 ARTICLE 3 

THE SECURITIES 

Section 3.1 Title and Terms. 

(a) The aggregate number of CVRs in respect of which CVR Certificates may be authenticated and
delivered under this CVR Agreement is limited to a number equal to
[—]1
, except for Securities authenticated and delivered upon registration of transfer of, or in exchange for, or
in lieu of, other Securities pursuant to Section 3.4, 3.5, 3.6 or 6.6. From and after the Effective Time, the Company shall not be permitted to issue any CVRs that have the right to receive any portion of the Milestone Payments or the Net Sales
Payments, except as provided and in accordance with the terms and conditions of the Merger Agreement. 
 (b) The
Securities shall be known and designated as the “Series A Contingent Value Rights” of the Company. 

(c) On each Net Sales Payment Date, the Company shall pay to the Trustee, by wire transfer to the account designated by
the Trustee, the Net Sales Payment due, if any, in respect of the Net Sales Measuring Period ended immediately preceding such Net Sales Payment Date, and the Trustee shall pay the Holders of the Securities as of such Net Sales Payment Date, a pro
rata portion of such Net Sales Payment based on the number of CVRs held by each Holder as of such date. Notwithstanding the foregoing, the Company’s obligations to pay any Net Sales Payment shall terminate in its entirety on the Net Sales
Payment Termination Date. 
 (d) On each Milestone Payment Date, the Company shall pay to the Trustee, by wire
transfer to the account designated by the Trustee, the applicable Milestone Payment, and the Trustee shall pay to the Holders of the Securities as of such Milestone Payment Date, a pro rata portion of such Milestone Payment based on the number of
CVRs held by each Holder as of such date. Notwithstanding the foregoing, the Company’s obligations to pay any Milestone Payment shall terminate in its entirety if the corresponding Milestone for such Milestone Payment has not been achieved by
the Milestone Target Date. 
  

	1
	Insert total, as of the closing of the Merger, of all CVRs to be issued pursuant to the Merger Agreement. 

 

 18 

 (e) The Holders of the CVR Certificates, by acceptance thereof, agree that
no joint venture, partnership or other fiduciary relationship is created hereby or by the Securities. 
 (f)
Other than in the case of interest on amounts due and payable after the occurrence of an Event of Default or with respect to any CVR Shortfall, no interest or dividends shall accrue on any amounts payable in respect of the CVRs. 

(g) Except to the extent any portion of any CVR Payment is required to be treated as imputed interest pursuant to
applicable Law, the Parties hereto agree to treat the CVRs and all CVR Payments for all Tax purposes as additional consideration for the shares of Common Stock, the Options, the SARs and the RSUs pursuant to the Merger Agreement, and none of the
Parties hereto will take any position to the contrary on any Tax Return or for other Tax purposes except as required by applicable Law. The Company shall report imputed interest on the CVRs pursuant to Section 483 of the Code. 

(h) The CVRs and any interest thereon may be sold, assigned, pledged encumbered or in any manner transferred or disposed
of, in whole or in part, only in compliance with applicable United States federal and state securities Laws and, to the extent applicable, in accordance with Section 3.5 hereof. 

(i) The Holder of any CVR or CVR Certificate is not, and shall not, by virtue thereof, be entitled to any rights of a
holder of any Voting Securities or other equity security or other ownership interest of the Company or in any constituent company to the Merger, either at Law or in equity, and the rights of the Holders are limited to those contractual rights
expressed in this CVR Agreement. 
 (j) Except as provided in this CVR Agreement (including, without limitation,
Section 7.6), none of the Company or any of its Affiliates shall have any right to set-off any amounts owed or claimed to be owed by any Holder to any of them against such Holder’s Securities or any CVR Payment or other amount payable to
such Holder in respect of such Securities. 
 (k) In the event that all of the CVR Certificates not previously
cancelled shall have become due and payable pursuant to the terms hereof, all disputes with respect to amounts payable to the Holders brought pursuant to the terms and conditions of this CVR Agreement have been resolved, and the Company has paid or
caused to be paid or deposited with the Trustee all amounts payable to the Holders under this CVR Agreement (including any amounts determined in accordance with Section 7.6 herein), then this CVR Agreement shall cease to be of further effect
and shall be deemed satisfied and discharged. Notwithstanding the satisfaction and discharge of this CVR Agreement, the obligations of the Company under Section 4.7(c) shall survive. 

Section 3.2 Registrable Form. The Securities shall be issuable only in registered form. 

 

 19 

 Section 3.3 Execution, Authentication, Delivery and Dating. 

(a) The Securities shall be executed on behalf of the Company by its chairman of the Board of Directors or its president
or any vice president or its treasurer, but need not be attested. The signature of any of these officers on the Securities may be manual or facsimile. 

(b) Securities bearing the manual or facsimile signatures of individuals who were, at the time of execution, the proper
officers of the Company shall bind the Company, notwithstanding that such individuals or any of them have ceased to hold such offices prior to the authentication and delivery of such Securities or did not hold such offices at the date of such
Securities. 
 (c) At any time and from time to time after the execution and delivery of this CVR Agreement, the
Company may deliver Securities executed by the Company to the Trustee for authentication, together with a Company Order for the authentication and delivery of such Securities; and the Trustee, in accordance with such Company Order, shall
authenticate and deliver such Securities as provided in this CVR Agreement and not otherwise. 
 (d) Each
Security shall be dated the date of its authentication. 
 (e) No Security shall be entitled to any benefit
under this CVR Agreement or be valid or obligatory for any purpose unless there appears on such Security a certificate of authentication substantially in the form provided for herein duly executed by the Trustee, by manual or facsimile signature of
an authorized officer, and such certificate upon any Security shall be conclusive evidence, and the only evidence, that such Security has been duly authenticated and delivered hereunder and that the Holder is entitled to the benefits of this CVR
Agreement. 
 Section 3.4 Temporary Securities. 

(a) Pending the preparation of definitive Securities, the Company may execute, and upon Company Order, the Trustee shall
authenticate and deliver, temporary Securities which are printed, lithographed, typewritten, mimeographed or otherwise produced, substantially of the tenor of the definitive Securities in lieu of which they are issued and with such appropriate
insertions, omissions, substitutions and other variations as the officers executing such Securities may determine with the concurrence of the Trustee. Temporary Securities may contain such reference to any provisions of this CVR Agreement as may be
appropriate. Every temporary Security shall be executed by the Company and be authenticated by the Trustee upon the same conditions and in substantially the same manner, and with like effect, as the definitive Securities. 

(b) If temporary Securities are issued, the Company will cause definitive Securities to be prepared without unreasonable
delay. After the preparation of definitive Securities, the temporary Securities shall be exchangeable for definitive Securities upon surrender of the temporary Securities at the office or agency of the Company designated for such purpose pursuant to
Section 7.2, without charge to the Holder. Upon surrender for cancellation of any one or more temporary Securities, the Company shall execute and the Trustee shall authenticate and deliver in exchange therefor a like amount of definitive
Securities. Until so 
  

 20 

 
exchanged, the Temporary Securities shall in all respects be entitled to the same benefits under this CVR Agreement as definitive Securities. 

Section 3.5 Registration, Registration of Transfer and Exchange. 

(a) The Company shall cause to be kept at the office of the Trustee a register (the register maintained in such office
and in any other office or agency designated pursuant to Section 7.2 being herein sometimes referred to as the “Security Register”) in which, subject to such reasonable regulations as it may prescribe, the Company shall provide
for the registration of Securities and of transfers of Securities. The Trustee is hereby initially appointed “Security Registrar” for the purpose of registering Securities and transfers of Securities as herein provided. 

(b) Upon surrender for registration of transfer of any Security at the office or agency of the Company designated
pursuant to Section 7.2, the Company shall execute, and the Trustee shall authenticate and deliver, in the name of the designated transferee or transferees, one or more new CVR Certificates representing the same aggregate number of CVRs
represented by the CVR Certificate so surrendered that are to be transferred and the Company shall execute and the Trustee shall authenticate and deliver, in the name of the transferor, one or more new CVR Certificates representing the aggregate
number of CVRs represented by such CVR Certificate that are not to be transferred. 
 (c) At the option of the
Holder, CVR Certificates may be exchanged for other CVR Certificates that represent in the aggregate the same number of CVRs as the CVR Certificates surrendered at such office or agency. Whenever any CVR Certificates are so surrendered for exchange,
the Company shall execute, and the Trustee shall authenticate and deliver, the CVR Certificates which the Holder making the exchange is entitled to receive. 

(d) All Securities issued upon any registration of transfer or exchange of Securities shall be the valid obligations of
the Company, evidencing the same rights, and entitled to the same benefits under this CVR Agreement, as the Securities surrendered upon such registration of transfer or exchange. 

(e) Every Security presented or surrendered for registration of transfer or for exchange shall (if so required by the
Company or the Security Registrar) be duly endorsed, or be accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar, duly executed by the Holder thereof or his attorney duly authorized in
writing. 
 (f) No service charge shall be made for any registration of transfer or exchange of Securities, but
the Company may require payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in connection with any registration of transfer or exchange of Securities, other than exchanges pursuant to Section 3.4 or 6.6
not involving any transfer. 
 Section 3.6 Mutilated, Destroyed, Lost and Stolen Securities. 

(a) If (i) any mutilated Security is surrendered to the Trustee, or (ii) the Company and the Trustee receive
evidence to their satisfaction of the destruction, loss or theft of 
  

 21 

 
any Security, and there is delivered to the Company and the Trustee such security or indemnity as may be required by them to save each of them harmless, then, in the absence of notice to the
Company or the Trustee that such Security has been acquired by a bona fide purchaser, the Company shall execute and, upon delivery of a Company Order, the Trustee shall authenticate and deliver, in exchange for any such mutilated Security or in lieu
of any such destroyed, lost or stolen Security, a new CVR Certificate of like tenor and amount of CVRs, bearing a number not contemporaneously outstanding. 

(b) In case any such mutilated, destroyed, lost or stolen Security has become or is to become finally due and payable
within fifteen (15) days, the Company in its discretion may, instead of issuing a new CVR Certificate, pay to the Holder of such Security on the applicable Payment Date, as the case may be, all amounts due and payable with respect thereto.

 (c) Every new Security issued pursuant to this Section 3.6 in lieu of any destroyed, lost or stolen
Security shall constitute an original additional contractual obligation of the Company, whether or not the destroyed, lost or stolen Security shall be at any time enforceable by anyone, and shall be entitled to all benefits of this CVR Agreement
equally and proportionately with any and all other Securities duly issued hereunder. 
 (d) The provisions of
this Section are exclusive and shall preclude (to the extent lawful) all other rights and remedies with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities. 

Section 3.7 Payments with respect to CVR Certificates. Payment of any amounts pursuant to the CVRs shall be
made in such coin or currency of the United States of America as at the time is legal tender for the payment of public and private debts. The Company may, at its option, pay such amounts by wire transfer or check payable in such money. 

Section 3.8 Persons Deemed Owners. Prior to the time of due presentment for registration of transfer, the
Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name any Security is registered as the owner of such Security for the purpose of receiving payment on such Security and for all other purposes whatsoever,
whether or not such Security be overdue, and neither the Company, the Trustee nor any agent of the Company or the Trustee shall be affected by notice to the contrary. 

Section 3.9 Cancellation. All Securities surrendered for payment, registration of transfer or exchange shall,
if surrendered to any Person other than the Trustee, be delivered to the Trustee and shall be promptly canceled by it. The Company may at any time deliver to the Trustee for cancellation any Securities previously authenticated and delivered
hereunder which the Company may have acquired in any manner whatsoever, and all Securities so delivered shall be promptly canceled by the Trustee. No Securities shall be authenticated in lieu of or in exchange for any Securities canceled as provided
in this Section, except as expressly permitted by this CVR Agreement. All cancelled Securities held by the Trustee shall be destroyed and a certificate of destruction shall be issued by the Trustee to the Company, unless otherwise directed by a
Company Order. 
  

 22 

 ARTICLE 4 

THE TRUSTEE 

Section 4.1 Certain Duties and Responsibilities. (a) With respect to the Holders, the Trustee, prior to
the occurrence of an Event of Default (as defined in Section 8.1) with respect to the Securities and after the curing or waiving of all Events of Default which may have occurred, undertakes to perform such duties and only such duties as are
specifically set forth in this CVR Agreement and no implied covenants shall be read into this CVR Agreement against the Trustee. In case an Event of Default with respect to the Securities has occurred (which has not been cured or waived), the
Trustee shall exercise such of the rights and powers vested in it by this CVR Agreement, and use the same degree of care and skill in their exercise, as a prudent person would exercise or use under the circumstances in the conduct of his own
affairs. 
 (b) In the absence of bad faith on its part, prior to the occurrence of an Event of Default and
after the curing or waiving of all such Events of Default which may have occurred, the Trustee may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon certificates or opinions furnished to
the Trustee which conform to the requirements of this CVR Agreement; but in the case of any such certificates or opinions which by any provision hereof are specifically required to be furnished to the Trustee, the Trustee shall be under a duty to
examine the same to determine whether or not they conform to the requirements of this CVR Agreement. 
 (c) No
provision of this CVR Agreement shall be construed to relieve the Trustee from liability for its own negligent action, its own negligent failure to act, or its own willful misconduct, except that (i) this Subsection (c) shall not be
construed to limit the effect of Subsections (a) and (b) of this Section; (ii) the Trustee shall not be liable for any error of judgment made in good faith by a Responsible Officer, unless it shall be proved that the Trustee was
negligent in ascertaining the pertinent facts; and (iii) the Trustee shall not be liable with respect to any action taken or omitted to be taken by it in good faith in accordance with the direction of the Holders pursuant to Section 8.9
relating to the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee, under this CVR Agreement. 

(d) Whether or not therein expressly so provided, every provision of this CVR Agreement relating to the conduct or
affecting the liability of or affording protection to the Trustee shall be subject to the provisions of this Section. 

Section 4.2 Certain Rights of Trustee. Subject to the provisions of Section 4.1, including without
limitation, the duty of care that the Trustee is required to exercise upon the occurrence of an Event of Default: 

(a) the Trustee may rely and shall be protected in acting or refraining from acting upon any resolution, certificate,
statement, instrument, opinion, report, notice, request, direction, consent, order, bond, debenture, note, other evidence of indebtedness or other paper or document believed by it to be genuine and to have been signed or presented by the proper
party or parties and the Trustee need not investigate any fact or matter stated in the document; 
  

 23 

 (b) any request or direction or order of the Company mentioned herein shall
be sufficiently evidenced by a Company Request or Company Order and any resolution of the Board of Directors may be sufficiently evidenced by a Board Resolution and the Trustee shall not be liable for any action it takes or omits to take in good
faith reliance thereon; 
 (c) whenever in the administration of this CVR Agreement the Trustee shall deem it
desirable that a matter be proved or established prior to taking, suffering or omitting any action hereunder, the Trustee (unless other evidence be herein specifically prescribed) may, in the absence of bad faith on its part, rely upon an
Officers’ Certificate and the Trustee shall not be liable for any action it takes or omits to take in good faith reliance thereon or an Opinion of Counsel; 

(d) the Trustee may consult with counsel and the written advice of such counsel or any Opinion of Counsel shall be full
and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in good faith and in accordance with such advice or Opinion of Counsel; 

(e) the Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this CVR Agreement
at the request or direction of any of the Holders pursuant to this CVR Agreement, unless such Holders shall have offered to the Trustee reasonable security or indemnity against the costs, expenses and liabilities which might be incurred by it in
compliance with such request or direction; 
 (f) the Trustee shall not be bound to make any investigation into
the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order, approval, appraisal, bond, debenture, note, coupon, security, or other paper or document, but the Trustee in its
discretion may make such further inquiry or investigation into such facts or matters as it may see fit, and if the Trustee shall determine to make such further inquiry or investigation, it shall be entitled to examine the books, records and premises
of the Company, personally or by agent or attorney; 
 (g) the Trustee may execute any of the trusts or powers
hereunder or perform any duties hereunder either directly or by or through agents or attorneys and the Trustee shall not be responsible for any misconduct or negligence on the part of any agent or attorney appointed with due care by it hereunder;
and 
 (h) the Trustee shall not be liable for any action taken, suffered or omitted to be taken by it in good
faith and believed by it to be authorized or within the discretion or rights or powers conferred upon it by this CVR Agreement. 

Section 4.3 Notice of Default. If a default occurs hereunder with respect to the Securities, the Trustee
shall give the Holders notice of any such default actually known to it as and to the extent applicable and provided by the Trust Indenture Act; provided, however, that in the case of any default of the character specified in Section 8.1(b) with
respect to the Securities, no notice to Holders shall be given until at least thirty (30) days after the occurrence thereof. For the purpose of this Section 4.3, the term “default” means any event that is, or after notice or
lapse of time or both would become, an Event of Default with respect to the Securities. 
  

 24 

 Section 4.4 Not Responsible for Recitals or Issuance of
Securities. The Trustee shall not be accountable for the Company’s use of the Securities or the proceeds from the Securities. The recitals contained herein and in the Securities, except the Trustee’s certificates of authentication,
shall be taken as the statements of the Company, and the Trustee assumes no responsibility for their correctness. The Trustee makes no representations as to the validity or sufficiency of this CVR Agreement or of the Securities. 

Section 4.5 May Hold Securities. The Trustee, any Paying Agent, Security Registrar or any other agent of
the Company, in its individual or any other capacity, may become the owner or pledgee of Securities, and, subject to Sections 4.8 and 4.13, may otherwise deal with the Company with the same rights it would have if it were not Trustee, Paying Agent,
Security Registrar or such other agent. 
 Section 4.6 Money Held in Trust. Money held by the
Trustee in trust hereunder need not be segregated from other funds except to the extent required by Law. The Trustee shall be under no liability for interest on any money received by it hereunder. 

Section 4.7 Compensation and Reimbursement. The Company agrees: 

(a) to pay to the Trustee from time to time reasonable compensation for all services rendered by it hereunder in such
amount as the Company and the Trustee shall agree from time to time (which compensation shall not be limited by any provision of Law in regard to the compensation of a trustee of an express trust); 

(b) except as otherwise expressly provided herein, to reimburse the Trustee upon its request for all reasonable expenses,
disbursements and advances incurred or made by the Trustee in accordance with any provision of this CVR Agreement (including the reasonable compensation and the reasonable expenses and disbursements of its agents and counsel), except any such
expense, disbursement or advance as may be attributable to the Trustee’s negligence or willful misconduct; and 

(c) to indemnify the Trustee and each of its agents, officers, directors and employees (each an “indemnitee”)
for, and to hold it harmless against, any loss, liability or expense (including attorneys fees and expenses) incurred without negligence or bad faith on its part, arising out of or in connection with the acceptance or administration of this trust
and the performance of its duties hereunder, including the reasonable costs and expenses of defending itself against any claim or liability in connection with the exercise or performance of any of its powers or duties hereunder. The Company’s
payment obligations pursuant to this Section shall survive the termination of this CVR Agreement. When the Trustee incurs expenses after the occurrence of an Event of Default specified in Section 8.1(c) or 8.1(d) with respect to the Company,
the expenses are intended to constitute expenses of administration under bankruptcy Laws. 
 Section 4.8
Disqualification; Conflicting Interests. 
 (a) If applicable, to the extent that the Trustee or the
Company determines that the Trustee has a conflicting interest within the meaning of the Trust Indenture Act, the Trustee shall, within ninety (90) days after ascertaining that it has such conflicting interest, either

  

 25 

 
eliminate such conflicting interest or resign to the extent and in the manner provided by, and subject to the provisions of, the Trust Indenture Act and this CVR Agreement. The Company shall take
prompt steps to have a successor appointed in the manner provided in this CVR Agreement. 
 (b) In the event the
Trustee shall fail to comply with the foregoing subsection 4.8(a), the Trustee shall, within ten (10) days of the expiration of such ninety (90) day period, transmit a notice of such failure to the Holders in the manner and to the extent
provided in the Trust Indenture Act and this CVR Agreement. 
 (c) If the Trustee fails to comply with
Section 4.8(a) after written request therefore by the Company or any Holder, any Holder of any Security who has been a bona fide Holder for at least six (6) months may on behalf of himself and all others similarly situated, petition any
court of competent jurisdiction for the removal of such Trustee and the appointment of a successor Trustee. 

Section 4.9 Corporate Trustee Required; Eligibility. There shall at all times be a Trustee hereunder which
satisfies the applicable requirements of Sections 310(a)(1) and (5) of the Trust Indenture Act and has a combined capital and surplus of at least one hundred fifty million dollars ($150,000,000). If such corporation publishes reports of
condition at least annually, pursuant to Law or to the requirements of a supervising or examining authority, then for the purposes of this Section 4.9, the combined capital and surplus of such corporation shall be deemed to be its combined
capital and surplus as set forth in its most recent report of condition so published. If at any time the Trustee shall cease to be eligible in accordance with the provisions of this Section, it shall resign immediately in the manner and with the
effect hereinafter specified in this Article. 
 Section 4.10 Resignation and Removal; Appointment of Successor.

 (a) No resignation or removal of the Trustee and no appointment of a successor Trustee pursuant to this
Article shall become effective until the acceptance of appointment by the successor Trustee under Section 4.11. 

(b) The Trustee, or any trustee or trustees hereafter appointed, may resign at any time by giving written notice thereof
to the Company. If an instrument of acceptance by a successor Trustee shall not have been delivered to the Trustee within thirty (30) days after the giving of such notice of resignation, the resigning Trustee may petition any court of competent
jurisdiction for the appointment of a successor Trustee. 
 (c) The Trustee may be removed at any time by an act
of the Majority Holders, delivered to the Trustee and to the Company. 
 (d) If at any time: 

(1) the Trustee shall fail to comply with Section 4.8 after written request therefor by the Company
or by any Holder who has been a bona fide Holder of a Security for at least six months, or 
  

 26 

 (2) the Trustee shall cease to be eligible under
Section 4.9 and shall fail to resign after written request therefor by the Company or by any such Holder, or 

(3) the Trustee shall become incapable of acting or shall be adjudged a bankrupt or insolvent, or a
receiver of the Trustee or of its property shall be appointed, or any public officer shall take charge or control of the Trustee or of its property or affairs for the purpose of rehabilitation, conservation or liquidation, then, in any case,
(i) the Company, by a Board Resolution, may remove the Trustee, or (ii) the Holder of any Security who has been a bona fide Holder of a Security for at least six months may, on behalf of himself and all others similarly situated, petition
any court of competent jurisdiction for the removal of the Trustee and the appointment of a successor Trustee. 

(e) If the Trustee shall resign, be removed or become incapable of acting, or if a vacancy shall occur in the office of
Trustee for any cause, the Company, by a Board Resolution, shall promptly appoint a successor Trustee. If, within one year after any removal by Holders of a majority of the Outstanding Securities, a successor Trustee shall be appointed by act of the
Holders of a majority of the Outstanding Securities delivered to the Company and the retiring Trustee the successor Trustee so appointed shall, forthwith upon its acceptance of such appointment in accordance with Section 4.11, become the
successor Trustee and supersede the successor Trustee appointed by the Company. If no successor Trustee shall have been so appointed by the Company or the Holders of the Securities and accepted appointment within sixty (60) days after the
retiring Trustee tenders its resignation or is removed, the retiring Trustee may, or, the Holder of any Security who has been a bona fide Holder for at least six (6) months may on behalf of himself and all others similarly situated, petition
any court of competent jurisdiction for the appointment of a successor Trustee. 
 (f) The Company shall give
notice of each resignation and each removal of the Trustee and each appointment of a successor Trustee by mailing written notice of such event by first-class mail, postage prepaid, to the Holders of Securities as their names and addresses appear in
the Security Register. Each notice shall include the name of the successor Trustee and the address of its Corporate Trust Office. If the Company fails to send such notice within ten (10) days after acceptance of appointment by a successor
Trustee, it shall not be a default hereunder but the successor Trustee shall cause the notice to be mailed at the expense of the Company. 

Section 4.11 Acceptance of Appointment of Successor. 

(a) Every successor Trustee appointed hereunder shall execute, acknowledge and deliver to the Company and to the retiring
Trustee an instrument accepting such appointment, and thereupon the resignation or removal of the retiring Trustee shall become effective and such successor Trustee, without any further act, deed or conveyance, shall become vested with all the
rights, powers, trusts and duties of the retiring Trustee; but, upon request of the Company or the successor Trustee, such retiring Trustee shall, upon payment of its charges, execute and deliver an instrument transferring to such successor Trustee
all the rights, powers and trusts of the retiring Trustee, and shall duly assign, transfer and deliver to such successor 

 

 27 

 
Trustee all property and money held by such retiring Trustee hereunder. Upon request of any such successor Trustee, the Company shall execute any and all instruments for more fully and certainly
vesting in and confirming to such successor Trustee all such rights, powers and trusts. 
 (b) No successor
Trustee shall accept its appointment unless at the time of such acceptance such successor Trustee shall be qualified and eligible under this Article. 

Section 4.12 Merger, Conversion, Consolidation or Succession to Business. Any corporation into which the
Trustee may be merged or converted or with which it may be consolidated, or any corporation resulting from any merger, conversion or consolidation to which the Trustee shall be a party, or any corporation succeeding to all or substantially all of
the corporate trust business of the Trustee, by sale or otherwise shall be the successor of the Trustee hereunder, provided such corporation shall be otherwise qualified and eligible under this Article, without the execution or filing of any paper
or any further act on the part of any of the Parties hereto. In case any Securities shall have been authenticated, but not delivered, by the Trustee then in office, any successor by merger, conversion, sale or consolidation to such authenticating
Trustee may adopt such authentication and deliver the Securities so authenticated with the same effect as if such successor Trustee had itself authenticated such Securities; and such certificate shall have the full force which it is anywhere in the
Securities or in this CVR Agreement provided that the certificate of the Trustee shall have; provided that the right to adopt the certificate of authentication of any predecessor Trustee shall apply only to its successor or successors by merger,
conversion or consolidation. 
 Section 4.13 Preferential Collection of Claims Against Company. If
and when the Trustee shall be or shall become a creditor, directly or indirectly, secured or unsecured, of the Company (or any other obligor upon the Securities), excluding any creditor relationship set forth in Section 311(b) of the Trust
Indenture Act, if applicable, the Trustee shall be subject to the applicable provisions of the Trust Indenture Act regarding the collection of claims against the Company (or any such other obligor). 

ARTICLE 5 

HOLDERS’ LISTS AND REPORTS BY THE TRUSTEE AND COMPANY 

Section 5.1 Company to Furnish Trustee Names and Addresses of Holders. The Company will furnish or cause to
be furnished to the Trustee (i) promptly after the issuance of the Securities, and semi-annually thereafter, a list, in such form as the Trustee may reasonably require, of the names and addresses of the Holders as of a recent date, and
(ii) at such times as the Trustee may request in writing, within thirty (30) days after receipt by the Company of any such request, a list, in such form as the Trustee may reasonably require, of the names and addresses of the Holders as of
a date not more than fifteen (15) days prior to the time such list is furnished; provided, however, that if and so long as the Trustee shall be the Security Registrar, no such list need be furnished. 

 

 28 

 Section 5.2 Preservation of Information; Communications to
Holders. 
 (a) The Trustee shall preserve, in as current a form as is reasonably practicable, the names and
addresses of Holders contained in the most recent list furnished to the Trustee as provided in Section 5.1 and the names and addresses of Holders received by the Trustee in its capacity as Security Registrar. The Trustee may destroy any list
furnished to it as provided in Section 5.1 upon receipt of a new list so furnished. 
 (b) The rights of
the Holders to communicate with other Holders with respect to their rights under this CVR Agreement and the corresponding rights and privileges of the Trustee shall be as provided by Section 312(b)(2) of the Trust Indenture Act, if applicable.

 (c) Every Holder of Securities, by receiving and holding the same, agrees with the Company and the Trustee
that neither the Company nor the Trustee shall be deemed to be in violation of Law or held accountable by reason of the disclosure of any such information as to the names and addresses of the Holders made pursuant to the Trust Indenture Act (if
applicable) regardless of the source from which such information was derived. 
 Section 5.3 Reports by
Trustee. 
 (a) Within sixty (60) days after December 31 of each year commencing with the
December 31 following the date of this CVR Agreement, the Trustee shall transmit to all Holders such reports concerning the Trustee and its actions under this CVR Agreement as may be required pursuant to the Trust Indenture Act to the extent
and in the manner provided pursuant thereto. The Trustee shall also comply with Section 313(b)(2) of the Trust Indenture Act, if applicable. The Trustee shall also transmit by mail all reports as required by Section 313(c) of the Trust
Indenture Act, if applicable. 
 (b) A copy of each such report shall, at the time of such transmission to the
Holders, be filed by the Trustee with each stock exchange, if any, upon which the Securities are listed, with the Commission and also with the Company. The Company will promptly notify the Trustee when the Securities are listed on any stock
exchange. 
 Section 5.4 Reports by Company. The Company shall: (a) file with the Trustee,
(i) within fifteen (15) days after the Company is required to file the same with the Commission, copies of the annual and quarterly reports and of the information, documents and other reports (or copies of such portions of any of the
foregoing as the Commission may from time to time by rules and regulations prescribe) which the Company is required to file with the Commission pursuant to Section 13 or Section 15(d) of the Exchange Act (such required information,
documents and other reports, together the “Exchange Act Documents”); and (ii) if the Company is not required to file Exchange Act Documents under Section 13 or 15(d) of the Exchange Act, within forty-five (45) days
after each calendar quarter of the Company (other than the last quarter of each calendar year), quarterly financial information and, within ninety (90) days after each calendar year of the Company, annual financial information that would be
required pursuant to Section 13 of the Exchange Act in respect of a security listed and registered on a national securities exchange as may be prescribed from time to time in such rules and regulations (provided that the Company also delivers
with, or includes within, the annual reports 
  

 29 

 
referred to in (i) and (ii) a calculation of Net Sales for the Products for the annual period to date), (iii) within ten (10) days after the Company files its annual report
with the Commission for any year if the Company is required to file Exchange Act Documents under Section 13 or 15(d) of the Exchange Act, or if the Company is not required to file Exchange Act Documents under Section 13 or 15(d) of the
Exchange Act within ninety (90) days after each calendar year, a Net Sales Statement with respect to the last completed calendar year, and (iv) within four (4) Business Days after the occurrence of any Milestone, a notice setting
forth the Milestone that occurred, the amount of the Milestone Payment payable in connection therewith and the applicable Milestone Payment Date; (b) file with the Trustee such additional information, documents and reports with respect to
compliance by the Company with the conditions and covenants of this CVR Agreement as may be required from time to time by the rules and regulations of the Commission, and (c) make available to the Holders on the Company’s website as of an
even date with the filing of such materials with the Trustee, the information, documents and reports required to be filed by the Company pursuant to subsections (a) or (b) of this Section 5.4. 

ARTICLE 6 

AMENDMENTS 

Section 6.1 Amendments Without Consent of Holders. Without the consent of any Holders, the Company and the
Trustee, at any time and from time to time, may enter into one or more amendments hereto or to the Securities, for any of the following purposes: 

(a) to convey, transfer, assign, mortgage or pledge to the Trustee as security for the Securities any property or assets;
or 
 (b) to evidence the succession of another Person to the Company, and the assumption by any such successor
of the covenants of the Company herein and in the Securities; or 
 (c) to add to the covenants of the Company
such further covenants, restrictions, conditions or provisions as its Board of Directors and the Trustee shall consider to be for the protection of the Holders of Securities, and to make the occurrence, or the occurrence and continuance, of a
default in any such additional covenants, restrictions, conditions or provisions an Event of Default permitting the enforcement of all or any of the several remedies provided in this CVR Agreement as herein set forth; provided, that in respect of
any such additional covenant, restriction, condition or provision, such amendment may provide for a particular period of grace after default (which period may be shorter or longer than that allowed in the case of other defaults) or may provide for
an immediate enforcement upon such an Event of Default or may limit the remedies available to the Trustee upon such an Event of Default or may limit the right of the Majority Holders to waive such an Event of Default; or 

(d) to cure any ambiguity, or to correct or supplement any provision herein or in the Securities which may be defective
or inconsistent with any other provision herein; provided, that such provisions shall not materially reduce the benefits of this CVR Agreement or the Securities to the Holders; or 

 

 30 

 (e) to make any other provisions with respect to matters or questions
arising under this CVR Agreement; provided, that such provisions shall not adversely affect the interests of the Holders; 

(f) to make any amendments or changes necessary to comply or maintain compliance with the Trust Indenture Act, if
applicable; or 
 (g) make any change that does not adversely affect the interests of the Holders. 

(h) Promptly following any amendment of this CVR Agreement or the Securities in accordance with this Section 6.1,
the Trustee shall notify the Holders of the Securities of such amendment; provided that any failure so to notify the Holders shall not affect the validity of such amendment. 

Section 6.2 Amendments with Consent of Holders. With the consent of the Majority Holders, by Act of said
Holders delivered to the Company and the Trustee, the Company (when authorized by a Board Resolution) and the Trustee may enter into one or more amendments hereto or to the Securities for the purpose of adding any provisions to or changing in any
manner or eliminating any of the provisions of this CVR Agreement or to the Securities or of modifying in any manner the rights of the Holders under this CVR Agreement or to the Securities; provided, however, that no such amendment shall, without
the consent of the Holder of each Outstanding Security affected thereby: 
 (a) modify in a manner adverse to
the Holders (i) any provision contained herein with respect to the termination of this CVR Agreement or the Securities, (ii) the time for payment and amount of any Net Sales Payment or any Milestone Payment, or otherwise extend the time
for payment of the Securities or reduce the amounts payable in respect of the Securities or modify any other payment term or payment date. Notwithstanding the foregoing, each Holder of a Security, by acceptance thereof, consents to the optional
redemption provisions set forth in Article 11 hereof; 
 (b) reduce the number of CVRs, the consent of whose
Holders is required for any such amendment; or 
 (c) modify any of the provisions of this Section, except to
increase any such percentage or to provide that certain other provisions of this CVR Agreement cannot be modified or waived without the consent of the Holder of each Security affected thereby. 

It shall not be necessary for any Act of Holders under this Section to approve the particular form of any proposed
amendment, but it shall be sufficient if such Act shall approve the substance thereof. 
 Section 6.3
Execution of Amendments. In executing any amendment permitted by this Article, the Trustee (subject to Section 4.1) shall be fully protected in relying upon an Opinion of Counsel stating that the execution of such amendment is authorized
or permitted by this CVR Agreement. The Trustee shall execute any amendment authorized pursuant to this Article if the amendment does not adversely affect the Trustee’s own rights, 

 

 31 

 
duties or immunities under this CVR Agreement or otherwise. Otherwise, the Trustee may, but need not, execute such amendment. 

Section 6.4 Effect of Amendments; Notice to Holders. 

(a) Upon the execution of any amendment under this Article, this CVR Agreement and the Securities shall be modified in
accordance therewith, and such amendment shall form a part of this CVR Agreement and the Securities for all purposes; and every Holder of Securities theretofore or thereafter authenticated and delivered hereunder shall be bound thereby. 

(b) Promptly after the execution by the Company and the Trustee of any amendment pursuant to the provisions of this
Article, the Company shall mail a notice thereof by first class mail to the Holders of Securities at their addresses as they shall appear on the Security Register, setting forth in general terms the substance of such amendment. Any failure of the
Company to mail such notice, or any defect therein, shall not, however, in any way impair or affect the validity of any such amendment. 

Section 6.5 Conformity with Trust Indenture Act. Every amendment executed pursuant to this Article shall
conform to the applicable requirements of the Trust Indenture Act, if any. 
 Section 6.6 Reference in
Securities to Amendments. If an amendment changes the terms of a Security, the Trustee may require the Holder of the Security to deliver it to the Trustee. Securities authenticated and delivered after the execution of any amendment pursuant to
this Article may, and shall if required by the Trustee, bear a notation in form approved by the Trustee as to any matter provided for in such amendment. If the Company shall so determine, new Securities so modified as to conform, in the opinion of
the Trustee and the Board of Directors, to any such amendment may be prepared and executed by the Company and authenticated and delivered by the Trustee in exchange for Outstanding Securities. Failure to make the appropriate notation or to issue a
new Security shall not affect the validity of such amendment. 
 ARTICLE 7 

COVENANTS 

Section 7.1 Payment of Amounts, if any, to Holders. The Company will duly and punctually pay the amounts, if
any, on the Securities in accordance with the terms of the Securities and this CVR Agreement. Such amounts shall be considered paid on the applicable Payment Date if on such date the Trustee or the Paying Agent holds in accordance with this CVR
Agreement money sufficient to pay all such amounts then due. Notwithstanding any other provision of this CVR Agreement, the Company or any of its Affiliates (including the Surviving Corporation, as applicable), the Trustee or the Paying Agent, shall
be entitled to deduct and withhold, or cause to be deducted and withheld, from amounts (including CVRs) otherwise payable pursuant to this CVR Agreement or the Merger Agreement to any holder of shares of Common Stock, Options, SARs, RSUs or CVRs,
such amounts as the Company or any of its Affiliates, the Trustee or the Paying Agent is required to deduct and withhold with respect to the making of such payment under the Internal Revenue Code of 1986, as amended, or any provision

  

 32 

 
of state, local or foreign Tax Law. To the extent that amounts are so withheld by the Company or any of its Affiliates, the Trustee or the Paying Agent, such withheld amounts shall be
(a) paid over to the applicable Governmental Entity in accordance with applicable Law and (b) treated for all purposes of this CVR Agreement as having been paid to such Holder in respect of which such deduction and withholding was made by
the Company or any of its Affiliates, the Trustee or the Paying Agent, as the case may be. The consent of Holder shall not be required for any such withholding. 

Section 7.2 Maintenance of Office or Agency. 

(a) As long as any of the Securities remain Outstanding, the Company will maintain in the Borough of Manhattan, The City
of New York, an office or agency (i) where Securities may be presented or surrendered for payment, (ii) where Securities may be surrendered for registration of transfer or exchange and (iii) where notices and demands to or upon the
Company in respect of the Securities and this CVR Agreement may be served. The office or agency of the Trustee at [—] shall be such office or agency of the Company, unless the Company shall designate
and maintain some other office or agency for one or more of such purposes. The Company or any of its Subsidiaries may act as Paying Agent, registrar or transfer agent; provided that such Person shall take appropriate actions to avoid the commingling
of funds. The Company will give prompt written notice to the Trustee of any change in the location of any such office or agency. If at any time the Company shall fail to furnish the Trustee with the address thereof, such presentations, surrenders,
notices and demands may be made or served at the Corporate Trust Office of the Trustee, and the Company hereby appoints the Trustee as its agent to receive all such presentations, surrenders, notices and demands. 

(b) The Company may from time to time designate one or more other offices or agencies (in or outside of The City of New
York) where the Securities may be presented or surrendered for any or all such purposes, and may from time to time rescind such designation; provided, however, that no such designation or rescission shall in any manner relieve the Company of its
obligation to maintain an office or agency in the Borough of Manhattan, The City of New York for such purposes. The Company will give prompt written notice to the Trustee of any such designation or rescission and any change in the location of any
such office or agency. 
 Section 7.3 Money for Security Payments to Be Held in Trust. 

(a) If the Company or any of its Subsidiaries shall at any time act as the Paying Agent, it will, on or before the
Payment Date, as the case may be, segregate and hold in trust for the benefit of the Holders all sums held by such Paying Agent for payment on the Securities until such sums shall be paid to the Holders as herein provided, and will promptly notify
the Trustee of any default by the Company in making payment on the Securities. 
 (b) Whenever the Company shall
have one or more Paying Agents for the Securities, it will, on or before a Payment Date deposit with a Paying Agent a sum in same day funds sufficient to pay the amount, if any, so becoming due; such sum to be held in trust for the benefit of the
Persons entitled to such amount, and (unless such Paying Agent is the Trustee) the Company will promptly notify the Trustee of such action or any failure so to act. 

 

 33 

 (c) The Company will cause each Paying Agent other than the Trustee to
execute and deliver to the Trustee an instrument in which such Paying Agent shall agree with the Trustee, subject to the provisions of this Section, that (i) such Paying Agent will hold all sums held by it for the payment of any amount payable
on Securities in trust for the benefit of the Persons entitled thereto until such sums shall be paid to such Persons or otherwise disposed of as herein provided and will notify the Trustee of the sums so held and (ii) that it will give the
Trustee notice of any failure by the Company (or by any other obligor on the Securities) to make any payment on the Securities when the same shall be due and payable. 

(d) Any money deposited with the Trustee or any Paying Agent, or then held by the Company, in trust for the payment on
any Security and remaining unclaimed for one year after the Payment Date shall be paid to the Company on Company Request, or (if then held by the Company) shall be discharged from such trust; and the Holder of such Security shall thereafter, as an
unsecured general creditor, look only to the Company for payment thereof, and all liability of the Trustee or such Paying Agent with respect to such trust money shall thereupon cease. 

Section 7.4 Certain Purchases and Sales. Nothing contained herein shall prohibit the Company or any of its
Subsidiaries or Affiliates from acquiring in open market transactions, private transactions or otherwise, the Securities. 

Section 7.5 Books and Records. The Company shall keep, and shall cause its Subsidiaries to keep, true,
complete and accurate records in sufficient detail to enable the amounts payable under this CVR Agreement to be determined by the Holders and their consultants or professional advisors, for a period of three (3) years following the end of any
Net Sales Measuring Period. 
 Section 7.6 Audits. 

(a) Upon the written request of the Majority Holders and no more than once during any calendar year, and upon reasonable
notice, the Company shall provide an independent certified public accounting firm of nationally recognized standing selected by the Majority Holders and the Company (the “Independent Accountant”) with access during normal business
hours to such of the records of the Company as may be reasonably necessary to verify the accuracy of the Net Sales Statements and the figures underlying the calculations set forth therein for any period within the preceding three (3) years that
has not previously been audited in accordance with this Section 7.6. The Company shall pay for the fees charged by the Independent Accountant in the event that the Independent Accountant determines that the amount paid by the Company is more
than ten percent (10%) below the amount due; provided, however, that the Majority Holders shall pay for the fees charged by such Independent Accountant in the event that the Independent Accountant determines that the amount paid by the Company
is equal to or less than ten percent (10%) below the amount due, which amount the Company may deduct from any future CVR Payments payable pursuant to this CVR Agreement. The Independent Accountant shall disclose to the Majority Holders only the
amounts that the Independent Accountant believes to be due and payable by the Company, details concerning any discrepancy from the amount paid and the amount due, and shall disclose no other information revealed in such audit. The Independent
Accountant shall provide the Company with a copy of 
  

 34 

 
all disclosures made to the Majority Holders. This covenant shall survive the termination of this CVR Agreement for a period of three (3) years; provided that the Holders shall only be
entitled to one audit following termination of this CVR Agreement. 
 (b) If the Independent Accountant
concludes that any Net Sales Payment amount should have been greater than the Net Sales Payment set forth in an applicable Net Sales Statement (the difference being the “CVR Shortfall”), the Company shall pay the CVR Shortfall,
within six (6) months of the date the Majority Holders deliver to the Company the Independent Accountant’s written report (the “Shortfall Report”); provided that the CVR Shortfall amount shall bear interest at the
Shortfall Interest Rate beginning from thirty (30) days after the date the Majority Holders deliver to the Company the Shortfall Report until payment is made to the Trustee. The decision of such Independent Accountant shall be final, conclusive
and binding on the Company and the Holders, shall be non-appealable and shall not be subject to further review. 

(c) Upon the expiration of three (3) years following the end of any Net Sales Measuring Period, the calculation of
the Net Sales Payment payable with respect to such Net Sales Measuring Period shall be conclusive and binding on each Holder, and the Company shall be released from any liability or accountability with respect to payments in respect of such Net
Sales Measuring Period in excess of such Net Sales Payment. 
 (d) Each person seeking to receive information
from the Company in connection with a review or audit shall enter into, and shall cause its accounting firm to enter into, a reasonable and mutually satisfactory confidentiality agreement with the Company obligating such party to retain all such
financial information disclosed to such party in confidence pursuant to such confidentiality agreement. 
 (e)
The Company shall not, and shall cause its Affiliates not to, enter into any license or distribution agreement with any third party (other than the Company or its Affiliates) with respect to any Product unless such agreement contains provisions that
would allow any Independent Accountant appointed pursuant to this Section 7.6 such access to the records of the other party to such license or distribution agreement as may be reasonably necessary to perform its duties pursuant to this
Section 7.6; provided that the Company and its Affiliates shall not be required to amend any Existing Licenses. The Parties agree that, if the Company or its Affiliates have exercised audit rights under any license or distribution agreement
prior to the Majority Holders’ request for an audit under this Section 7.6 and under such license or distribution agreement the Company and its Affiliates cannot request another audit, the results of the Company’s prior audit of such
licensee or distributor will be used for purposes of the audit requested by the Majority Holders under this Section 7.6 and that the Company shall not have any further obligation to provide access to an Independent Accountant with respect to
such licensee until such time as the Company may again exercise its rights of audit under the license agreement with such licensee. 

Section 7.7 Listing of CVRs. The Company hereby covenants and agrees to use reasonable best efforts to cause
the Securities to be approved for listing (subject to notice of issuance) for trading on the Nasdaq Capital Market and will use its reasonable best efforts to maintain such listing for so long as any CVRs remain Outstanding. 

 

 35 

 Section 7.8 Conflicting Arrangements. So long as any of the
Securities remain Outstanding, the Company shall not enter into any binding agreement, arrangement or understanding, or take or permit to be taken any action, which would, or would reasonably be expected to, delay or prevent the Company’s
ability to timely make any CVR Payment that becomes due under this CVR Agreement. 
 Section 7.9 Product
Transfer. Subject to Article 9, so long as the Securities remain Outstanding, the Company and its Affiliates may not, directly or indirectly, by a sale or swap of assets, merger, reorganization, joint venture, lease, license or any other
transaction or arrangement, sell, transfer, convey or otherwise dispose of their respective rights in and to any Product to a third party (other than the Company or its Affiliates), unless at all times after any such sale, transfer, conveyance or
other disposition, the gross amounts invoiced for the Products by the applicable transferee (or the amounts of royalties, profit split payments and milestone payments, as described in clause (ii) of the definition of “Net Sales,” with
respect to Existing Licenses, as applicable) will be reflected in Net Sales in accordance with the terms hereunder (with the transferee substituted for the Company for purposes of the definition of “Net Sales”) as if such transferee was
the Company, and the contract for such sale, transfer, conveyance or other disposition (which the Company shall take all reasonable actions necessary to enforce in all material respects) shall provide for such treatment and shall require the
transferee to comply with the covenants in this Section 7.9 and Sections 7.6, 7.10 and 7.11 hereof to the same extent as the Company. For purposes of clarification, this Section 7.9 shall not apply to sales of Products made by the Company
or its Affiliates or ordinary course licensing arrangements between the Company and its Affiliates, on the one hand, and third party licensees, distributors and contract manufacturers, on the other hand, entered into in the ordinary course of
business for purposes of developing, manufacturing, distributing and selling Products and for which the gross amounts invoiced for sales of Products by the applicable third party licensee, distributor or contract manufacturer (or the amounts of
royalties, profit split payments and milestone payments, as described in clause (ii) of the definition of “Net Sales,” with respect to Existing Licenses, as applicable) will be reflected in Net Sales of such Products in accordance
with the terms of this Agreement. 
 Section 7.10 Milestones. The Company shall use Diligent Efforts
to achieve each of the Milestones; provided, however, that such obligation to use Diligent Efforts to achieve each of the Milestones shall terminate upon the Milestone Target Date. 

Section 7.11 Product Sale and Development. The Company shall use Diligent Efforts to obtain Regulatory
Approval for the Indications; provided, however, that such obligation to use Diligent Efforts to obtain such Regulatory Approval shall terminate upon the earlier of (a) the Net Sales Payment Termination Date and (b) on an
Indication-by-Indication basis, such time as the data generated in an appropriate clinical trial does not support further development of the Product described in clause (a) of the definition of “Product.” The Company shall use
Diligent Efforts to sell the Products for which the Company has obtained Regulatory Approval; provided, however, that such obligation to use Diligent Efforts to sell the Products shall terminate upon the Net Sales Payment Termination Date.

  

 36 

 Section 7.12 Notice of Default. The Company shall file with the
Trustee written notice of the occurrence of any Event of Default or other default under this CVR Agreement within five (5) business days of its becoming aware of any such Default or Event of Default. 

Section 7.13 Confidentiality. The Trustee and the Holders hereby agree that any confidential or non-public
information (including Net Sales Statements) they receive from or on behalf of the Company or any Affiliate of the Company, which receipt arises out of the transactions contemplated by this CVR Agreement (the “Confidential
Information”), shall: (a) not be used for any purpose other than for purposes permitted under this CVR Agreement; (b) not be used directly or indirectly in any way that is for competitive purposes; and (c) not be disclosed
by, and be kept confidential by, such Trustee and the Holders and its directors, officers, members, managers, employees, affiliates, and agents (collectively, “Representatives”); provided, however, that any such Confidential
Information may be disclosed only to their Representatives (including the Independent Accountant) who (i) need to know such Confidential Information and (ii) are bound in writing to a non-disclosure agreement no less restrictive than this
Section 7.13. It is understood that such Representatives shall be informed by the Trustee or the applicable Holder of the confidential nature of such Confidential Information, and that the Trustee or such Holder, as applicable, shall be
responsible for any disclosure or use made by its Representatives in breach of obligations under this CVR Agreement to the same extent as if such disclosure or use had been made directly by the Trustee or such Holder, as applicable. Each of the
Trustee and the Holders will as soon as practicable notify the Company of any breach of this CVR Agreement of which they become aware, and will use commercially reasonable efforts to assist and cooperate with the Company in minimizing the
consequences of such breach. “Confidential Information” shall not include any information that is (i) publicly available other than because of disclosure by the Trustee or the Holders or any of their respective Representatives or
(ii) is lawfully disclosed to the Trustee or Holders by sources (other than the Company or its Affiliates) rightfully in possession of the Confidential Information. If the Trustee, Holders or their respective Representatives are legally
required or requested to disclose any Confidential Information, they will in advance of such disclosure, unless otherwise prohibited by Law, promptly notify the Company of such request or requirement so that the Company may seek to avoid or minimize
the required disclosure and/or obtain an appropriate protective order or other appropriate relief to ensure that any Confidential Information so disclosed is maintained in confidence to the maximum extent possible by the person receiving the
disclosure, or, in the Company’s discretion, to waive compliance with the provisions of this CVR Agreement. In any such case, the Trustee and the Holders agree to cooperate and use reasonable efforts to avoid or minimize the required disclosure
and/or obtain such protective order or other relief. If, in the absence of a protective order or the receipt of a waiver hereunder, the Trustee, Holders or their respective Representatives are legally obligated to disclose any Confidential
Information, they will disclose only so much thereof to the party compelling disclosure as they believe in good faith, on the basis of advice of counsel, is required by Law. The Trustee and Holders shall give the Company prior written notice of the
specific Confidential Information that they believe they are required to disclose under such circumstances. All Confidential Information disclosed by or on behalf of the Company or any of its Affiliates shall be, and shall remain, the property of
the Company or such Affiliate. 
 Section 7.14 Non-Use of Name. Neither the Trustee nor the Holders
shall use the name, trademark, trade name, or logo of the Company, its Affiliates, or their respective 
  

 37 

 
employees in any publicity or news release relating to this CVR Agreement or its subject matter, without the prior express written permission of the Company. 

ARTICLE 8 

REMEDIES OF THE TRUSTEE AND HOLDERS 

ON EVENT OF DEFAULT 

Section 8.1 Event of Default Defined; Waiver of Default. “Event of Default” with respect to
the Securities, means each one of the following events which shall have occurred and be continuing (whatever the reason for such Event of Default and whether it shall be voluntary or involuntary or be effected by operation of Law or pursuant to any
judgment, decree or order of any court or any order, rule or regulation of any administrative or governmental body): 

(a) default in the payment of all or any part of any CVR Payment after a period of ten (10) Business Days after such
CVR Payment shall become due and payable on a Payment Date or otherwise; or 
 (b) material default in the
performance, or breach in any material respect, of any covenant or warranty of the Company in respect of the Securities (other than a covenant or warranty in respect of the Securities, a default in whose performance or whose breach is elsewhere in
this Section specifically dealt with), and continuance of such default or breach for a period of ninety (90) days after there has been given, by registered or certified mail, to the Company by the Trustee or to the Company and the Trustee by
the Majority Holders, a written notice specifying such default or breach and requiring it to be remedied and stating that such notice is a “Notice of Default” hereunder; or 

(c) a court having jurisdiction in the premises shall enter a decree or order for relief in respect of the Company in an
involuntary case under any applicable bankruptcy, insolvency or other similar Law now or hereafter in effect, or appointing a receiver, liquidator, assignee, custodian, trustee or sequestrator (or similar official) of the Company or for any
substantial part of its property or ordering the winding up or liquidation of its affairs, and such decree or order shall remain unstayed and in effect for a period of ninety (90) consecutive days; or 

(d) the Company shall commence a voluntary case under any applicable bankruptcy, insolvency or other similar Law now or
hereafter in effect, or consent to the entry of an order for relief in an involuntary case under any such Law, or consent to the appointment of or taking possession by a receiver, liquidator, assignee, custodian, trustee or sequestrator (or similar
official) of the Company or for any substantial part of its property, or make any general assignment for the benefit of creditors. 

If an Event of Default described above occurs and is continuing, then, and in each and every such case, either the
Trustee or the Trustee upon the written request of the Majority Holders by notice in writing to the Company (and to the Trustee if given by the Majority Holders), shall bring suit to protect the rights of the Holders, including to obtain payment for
any 
  

 38 

 
amounts then due and payable, which amounts shall bear interest at the Default Interest Rate until payment is made to the Trustee. 

The foregoing provisions, however, are subject to the condition that if, at any time after the Trustee shall have begun
such suit, and before any judgment or decree for the payment of the moneys due shall have been obtained or entered as hereinafter provided, the Company shall pay or shall deposit with the Trustee a sum sufficient to pay all amounts which shall have
become due (with interest upon such overdue amount at the Default Interest Rate to the date of such payment or deposit) and such amount as shall be sufficient to cover reasonable compensation to the Trustee, its agents, attorneys and counsel, and
all other expenses and liabilities incurred and all advances made, by the Trustee, and if any and all Events of Default under this CVR Agreement shall have been cured, waived or otherwise remedied as provided herein, then and in every such case the
Majority Holders, by written notice to the Company and to the Trustee, may waive all defaults with respect to the Securities, but no such waiver or rescission and annulment shall extend to or shall affect any subsequent default or shall impair any
right consequent thereof. 
 Section 8.2 Collection by the Trustee; the Trustee May Prove Payment
Obligations. The Company covenants that in case default shall be made in the payment of all or any part of the Securities when the same shall have become due and payable, whether at a Payment Date or otherwise, then upon demand of the Trustee,
the Company will pay to the Trustee for the benefit of the Holders of the Securities the whole amount that then shall have become due and payable on all Securities (with interest from the date due and payable to the date of such payment upon the
overdue amount at the Default Interest Rate); and in addition thereto, such further amount as shall be sufficient to cover the costs and expenses of collection, including reasonable compensation to the Trustee and each predecessor Trustee, their
respective agents, attorneys and counsel, and any expenses and liabilities incurred, and all advances made, by the Trustee and each predecessor Trustee, except as a result of its negligence or bad faith. 

The Trustee may in its discretion proceed to protect and enforce its rights and the rights of the Holders by such
appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any such rights, whether for the specific enforcement of any covenant or agreement in this CVR Agreement or in aid of the exercise of any power granted
herein, or to enforce any other remedy. 
 In case the Company shall fail forthwith to pay such amounts upon
such demand, the Trustee, in its own name and as trustee of an express trust, shall be entitled and empowered to institute any action or proceedings at Law or in equity for the collection of the sums so due and unpaid, and may prosecute any such
action or proceedings to judgment or final decree, and may enforce any such judgment or final decree against the Company or other obligor upon such Securities and collect in the manner provided by Law out of the property of the Company or other
obligor upon such Securities, wherever situated, the moneys adjudged or decreed to be payable. 
 In any
judicial proceedings relative to the Company or other obligor upon the Securities, irrespective of whether any amount is then due and payable with respect to the Securities, the Trustee is authorized: 

 

 39 

 (a) to file and prove a claim or claims for the whole amount owing and
unpaid in respect of the Securities, and to file such other papers or documents as may be necessary or advisable in order to have the claims of the Trustee (including any claim for reasonable compensation to the Trustee and each predecessor Trustee,
and their respective agents, attorneys and counsel, and for reimbursement of all expenses and liabilities incurred, and all advances made, by the Trustee and each predecessor Trustee, except as a result of negligence or bad faith) and of the Holders
allowed in any judicial proceedings relative to the Company or other obligor upon the Securities, or to their respective property; 

(b) unless prohibited by and only to the extent required by applicable Law, to vote on behalf of the Holders in any
election of a trustee or a standby trustee in arrangement, reorganization, liquidation or other bankruptcy or insolvency proceedings or person performing similar functions in comparable proceedings; and 

(c) to collect and receive any moneys or other property payable or deliverable on any such claims, and to distribute all
amounts received with respect to the claims of the Holders and of the Trustee on their behalf; and any trustee, receiver, or liquidator, custodian or other similar official is hereby authorized by each of the Holders to make payments to the Trustee,
and, in the event that the Trustee shall consent to the making of payments directly to the Holders, to pay to the Trustee such amounts as shall be sufficient to cover reasonable compensation to the Trustee, each predecessor Trustee and their
respective agents, attorneys and counsel, and all other expenses and liabilities incurred, and all advances made, by the Trustee and each predecessor Trustee, except as a result of its negligence or bad faith, and all other amounts due to the
Trustee or any predecessor Trustee pursuant to Section 4.6. To the extent that such payment of reasonable compensation, expenses, disbursements, advances and other amounts out of the estate in any such proceedings shall be denied for any
reason, payment of the same shall be secured by a lien on, and shall be paid out of, any and all distributions, dividends, moneys, securities and other property which the Holders may be entitled to receive in such proceedings, whether in liquidation
or under any plan of reorganization or arrangement or otherwise. 
 Nothing herein contained shall be deemed to
authorize the Trustee to authorize or consent to or vote for or accept or adopt on behalf of any Holder any plan of reorganization, arrangement, adjustment or composition affecting the Securities, or the rights of any Holder thereof, or to authorize
the Trustee to vote in respect of the claim of any Holder in any such proceeding except, as aforesaid, to vote for the election of a trustee in bankruptcy or similar person. 

All rights of action and of asserting claims under this CVR Agreement, or under any of the Securities, may be enforced by
the Trustee without the possession of any of the Securities or the production thereof and any trial or other proceedings instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of judgment, subject
to the payment of the expenses, disbursements and compensation of the Trustee, each predecessor Trustee and their respective agents and attorneys, shall be for the ratable benefit of the Holders. 

 

 40 

 In any proceedings brought by the Trustee (and also any proceedings
involving the interpretation of any provision of this CVR Agreement to which the Trustee shall be a party) the Trustee shall be held to represent all the Holders, and it shall not be necessary to make any Holders of such Securities parties to any
such proceedings. 
 Section 8.3 Application of Proceeds. Any monies collected by the Trustee
pursuant to this Article in respect of any Securities shall be applied in the following order at the date or dates fixed by the Trustee upon presentation of the several Securities in respect of which monies have been collected and stamping (or
otherwise noting) thereon the payment in exchange for the presented Securities if only partially paid or upon surrender thereof if fully paid: 

FIRST: To the payment of costs and expenses in respect of which monies have been collected, including
reasonable compensation to the Trustee and each predecessor Trustee and their respective agents and attorneys and of all expenses and liabilities incurred, and all advances made, by the Trustee and each predecessor Trustee, except as a result of its
negligence or willful misconduct, and all other amounts due to the Trustee or any predecessor Trustee pursuant to Section 4.6; 

SECOND: To the payment of the whole amount then owing and unpaid upon all the Securities, with interest at
the Default Interest Rate on all such amounts, and in case such monies shall be insufficient to pay in full the whole amount so due and unpaid upon the Securities, then to the payment of such amounts without preference or priority of any security
over any other Security, ratably to the aggregate of such amounts due and payable; and 
 THIRD:
To the payment of the remainder, if any, to the Company or any other person lawfully entitled thereto. 

Section 8.4 Suits for Enforcement. In case an Event of Default has occurred, has not been waived and is
continuing, the Trustee may in its discretion proceed to protect and enforce the rights vested in it by this CVR Agreement by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any of such rights,
either at Law or in equity or in bankruptcy or otherwise, whether for the specific enforcement of any covenant or agreement contained in this CVR Agreement or in aid of the exercise of any power granted in this CVR Agreement or to enforce any other
legal or equitable right vested in the Trustee by this CVR Agreement or by Law. 
 Section 8.5
Restoration of Rights on Abandonment of Proceedings. In case the Trustee or any Holder shall have proceeded to enforce any right under this CVR Agreement and such proceedings shall have been discontinued or abandoned for any reason, or shall
have been determined adversely to the Trustee or to such Holder, then and in every such case the Company and the Trustee and the Holders shall be restored respectively to their former positions and rights hereunder, and all rights, remedies and
powers of the Company, the Trustee and the Holders shall continue as though no such proceedings had been taken. 

Section 8.6 Limitations on Suits by Holders. Subject to the right of the Majority Holders under
Section 7.6, no Holder of any Security shall have any right by virtue or 
  

 41 

 
by availing of any provision of this CVR Agreement to institute any action or proceeding at Law or in equity or in bankruptcy or otherwise upon or under or with respect to this CVR Agreement, or
for the appointment of a trustee, receiver, liquidator, custodian or other similar official or for any other remedy hereunder, unless such Holder previously shall have given to the Trustee written notice of default and of the continuance thereof, as
hereinbefore provided, and unless also the Majority Holders shall have made written request upon the Trustee to institute such action or proceedings in its own name as trustee hereunder and shall have offered to the Trustee such reasonable indemnity
as it may require against the costs, expenses and liabilities to be incurred therein or thereby and the Trustee for fifteen (15) days after its receipt of such notice, request and offer of indemnity shall have failed to institute any such
action or proceeding and no direction inconsistent with such written request shall have been given to the Trustee pursuant to Section 8.9. For the protection and enforcement of the provisions of this Section, each and every Holder and the
Trustee shall be entitled to such relief as can be given either at Law or in equity. 
 Section 8.7
Unconditional Right of Holders to Institute Certain Suits. Notwithstanding any other provision in this CVR Agreement and any provision of any Security, the right of any Holder of any Security to receive payment of the amounts payable in
respect of such Security on or after the respective due dates expressed in such Security, or to institute suit for the enforcement of any such payment on or after such respective dates, shall not be impaired or affected without the consent of such
Holder. 
 Section 8.8 Powers and Remedies Cumulative; Delay or Omission Not Waiver of Default.

 (a) Except as provided in Section 8.6, no right or remedy herein conferred upon or reserved to the
Trustee or to the Holders is intended to be exclusive of any other right or remedy, and every right and remedy shall, to the extent permitted by Law, be cumulative and in addition to every other right and remedy given hereunder or now or hereafter
existing at Law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other appropriate right or remedy. 

(b) No delay or omission of the Trustee or of any Holder to exercise any right or power accruing upon any Event of
Default occurring and continuing as aforesaid shall impair any such right or power or shall be construed to be a waiver of any such Event of Default or an acquiescence therein; and, subject to Section 8.6, every power and remedy given by this
CVR Agreement or by Law to the Trustee or to the Holders may be exercised from time to time, and as often as shall be deemed expedient, by the Trustee or by the Holders. 

Section 8.9 Control by Holders. 

(a) The Majority Holders shall have the right to direct the time, method, and place of conducting any proceeding for any
remedy available to the Trustee, or exercising any power conferred on the Trustee with respect to the Securities by this CVR Agreement; provided that such direction shall not be otherwise than in accordance with Law and the provisions of this CVR
Agreement; and provided further that (subject to the provisions of Section 4.1) the Trustee shall have the right to decline to follow any such direction if the Trustee, being advised by 

 

 42 

 
counsel, shall determine that the action or proceeding so directed may not lawfully be taken or if the Trustee in good faith by its board of directors, the executive committee, or a committee of
directors or responsible officers of the Trustee shall determine that the action or proceedings so directed would involve the Trustee in personal liability or if the Trustee in good faith shall so determine that the actions or forbearances specified
in or pursuant to such direction would be unduly prejudicial to the interests of Holders of the Securities not joining in the giving of said direction. 

(b) Nothing in this CVR Agreement shall impair the right of the Trustee in its discretion to take any action deemed
proper by the Trustee and which is not inconsistent with such direction or directions by Holders. 

Section 8.10 Waiver of Past Defaults. 

(a) In the case of a default or an Event of Default specified in clause (b), (c) or (d) of Section 8.1,
the Majority Holders may waive any such default or Event of Default, and its consequences except a default in respect of a covenant or provisions hereof which cannot be modified or amended without the consent of the Holder of each Security affected.
In the case of any such waiver, the Company, the Trustee and the Holders of the Securities shall be restored to their former positions and rights hereunder, respectively; but no such waiver shall extend to any subsequent or other default or impair
any right consequent thereon. 
 (b) Upon any such waiver, such default shall cease to exist and be deemed to
have been cured and not to have occurred, and any Event of Default arising therefrom shall be deemed to have been cured, and not to have occurred for every purpose of this CVR Agreement; but no such waiver shall extend to any subsequent or other
default or Event of Default or impair any right consequent thereon. 
 Section 8.11 The Trustee to Give
Notice of Default, But May Withhold in Certain Circumstances. The Trustee shall transmit to the Holders, as the names and addresses of such Holders appear on the Security Register (as provided under Section 313(c) of the Trust Indenture
Act, if applicable), notice by mail of all defaults which have occurred and are known to the Trustee, such notice to be transmitted within ninety (90) days after the occurrence thereof, unless such defaults shall have been cured before the
giving of such notice (the term “default” for the purposes of this Section being hereby defined to mean any event or condition which is, or with notice or lapse of time or both would become, an Event of Default); provided that, except in
the case of default in the payment of the amounts payable in respect of any of the Securities, the Trustee shall be protected in withholding such notice if and so long as the board of directors, the executive committee, or a trust committee of
directors or trustees and/or Responsible Officers of the Trustee in good faith determines that the withholding of such notice is in the interests of the Holders. 

Section 8.12 Right of Court to Require Filing of Undertaking to Pay Costs. All Parties to this CVR Agreement
agree, and each Holder of any Security by his acceptance thereof shall be deemed to have agreed, that any court may in its discretion require, in any suit for the enforcement of any right or remedy under this CVR Agreement or in any suit against the
Trustee for any action taken, suffered or omitted by it as the Trustee, the filing by any party litigant in 
  

 43 

 
such suit of an undertaking to pay the costs of such suit, and that such court may in its discretion assess reasonable costs, including attorneys’ fees, against any party litigant in such
suit, having due regard to the merits and good faith of the claims or defenses made by such party litigant; but the provisions of this Section 8.12 shall not apply to any suit instituted by the Trustee, to any suit instituted by any Holder or
group of Holders holding in the aggregate more than ten percent (10%) of the Securities Outstanding or to any suit instituted by any Holder for the enforcement of the payment of any Security on or after the due date expressed in such Security.

 ARTICLE 9 

CONSOLIDATION, MERGER, SALE OR CONVEYANCE 

Section 9.1 Company May Consolidate, etc., on Certain Terms. The Company covenants that it will not merge or
consolidate with or into any other Person or sell or convey all or substantially all of its assets to any Person, unless, (i) the Company shall be the continuing Person, or the successor Person or the Person which acquires by sale or conveyance
substantially all the assets of the Company (including the shares of Abraxis) shall be a Person organized under the Laws of the United States of America or any State thereof and shall expressly assume by an instrument supplemental hereto, executed
and delivered to the Trustee, in form satisfactory to the Trustee, the due and punctual payment of the Securities, according to their tenor, and the due and punctual performance and observance of all of the covenants and conditions of this CVR
Agreement to be performed or observed by the Company and (ii) the Company, or such successor Person, as the case may be, shall not, immediately after such merger or consolidation, or such sale or conveyance, be in default in the performance of
any such covenant or condition. 
 Section 9.2 Successor Person Substituted. 

(a) In case of any such consolidation, merger, sale or conveyance, and following such an assumption by the successor
Person, such successor Person shall succeed to and be substituted for the Company with the same effect as if it had been named herein. Such successor Person may cause to be signed, and may issue either in its own name or in the name of the Company
prior to such succession any or all of the Securities issuable hereunder which theretofore shall not have been signed by the Company and delivered to the Trustee; and, upon the order of such successor corporation instead of the Company and subject
to all the terms, conditions and limitations in this CVR Agreement prescribed, the Trustee shall authenticate and shall deliver any Securities which previously shall have been signed and delivered to the Trustee for authentication, and any
Securities which such successor corporation thereafter shall cause to be signed and delivered to the Trustee for that purpose. All of the Securities so issued shall in all respects have the same legal rank and benefit under this CVR Agreement as the
Securities theretofore or thereafter issued in accordance with the terms of this CVR Agreement as though all of such Securities had been issued at the date of the execution hereof. 

(b) In case of any such consolidation, merger, sale or conveyance, such changes in phraseology and form (but not in
substance) may be made in the Securities thereafter to be issued as may be appropriate. The successor entity to such consolidation, merger, sale or conveyance may satisfy the obligations of Section 5.4(a)(i) and (ii) of this CVR Agreement
by providing copies of such successor entity’s Exchange Act Documents in the case of Section 5.4(a)(i) or such successor entity’s financial information in the case of Section 5.4(a)(ii). 

 

 44 

 (c) In the event of any such sale, transfer or conveyance (other than a
conveyance by way of lease) the Company or any Person which shall theretofore have become such in the manner described in this Article shall be discharged from all obligations and covenants under this CVR Agreement and the Securities and may be
liquidated and dissolved. 
 Section 9.3 Opinion of Counsel to the Trustee. The Trustee, subject to
the provisions of Sections 4.1 and 4.2, shall receive an Officer’s Certificate and Opinion of Counsel, prepared in accordance with Sections 1.3 and 1.4, as conclusive evidence that any such consolidation, merger, sale or conveyance, and any
such assumption, and any such liquidation or dissolution, complies with the applicable provisions of this CVR Agreement, and if a supplemental agreement is required in connection with such transaction, such supplemental agreement complies with this
Article and that there has been compliance with all conditions precedent herein provided for or relating to such transaction. 

Section 9.4 Successors. All covenants, provisions and agreements in this CVR Agreement by or for the benefit
of the Company, the Trustee or the Holders shall bind and inure to the benefit of their respective successors, assigns, heirs and personal representatives, whether so expressed or not. The Company may assign this CVR Agreement without the prior
written consent of the other Parties to this CVR Agreement to one or more of its direct or indirect Subsidiaries, provided, however, that in the event of any such assignment the Company shall remain subject to its obligations and covenants
hereunder, including but not limited to its obligation to make any Net Sales Payments and any Milestone Payments. 
 ARTICLE
10 
 SUBORDINATION 

Section 10.1 Agreement to Subordinate. The Company agrees, and each Holder by accepting a Security hereunder
agrees, that the CVR Payments, all other obligations under this CVR Agreement and the Securities and any rights or claims relating thereto (collectively, the “Junior Obligations”) are subordinated in right of payment, to the extent
and in the manner provided in this Article 10, to the prior payment in full in cash or cash equivalents of all Senior Obligations of the Company (whether outstanding on the date hereof or hereafter created, incurred, assumed or guaranteed), and that
the subordination is for the benefit of the holders of such Senior Obligations. 
 Section 10.2
Liquidation; Dissolution; Bankruptcy. Upon any distribution to creditors of the Company in a liquidation or dissolution of the Company or in a bankruptcy, reorganization, insolvency, receivership or similar proceeding relating to the Company
or its property, in an assignment for the benefit of creditors or any marshaling of the Company’s assets and liabilities: 

(a) holders of Senior Obligations will be entitled to receive payment in full in cash or cash equivalents of all Senior
Obligations of the Company (including interest after the commencement of any bankruptcy proceeding at the rate specified in the applicable Senior Obligation, whether or not permitted under such bankruptcy proceedings) before the Holders will be
entitled to receive any payment of any kind with respect to the Junior Obligations; and 
  

 45 

 (b) until all Senior Obligations of the Company (as provided in clause
(a) above) are paid in full in cash or cash equivalents, any distribution to which Holders would be entitled but for this Article 10 will be made to holders of Senior Obligations of the Company, as their interests may appear. 

Section 10.3 Default on Senior Obligations. The Company may not make any payment or distribution to any
Holder in respect of Junior Obligations or acquire from any Holder for cash or property any Junior Obligations: 

(a) if any default on any Senior Obligations exceeding twenty-five million dollars ($25,000,000) in aggregate principal
amount would occur as a result of such payment, distribution or acquisition; 
 (b) during the continuance of
any payment default in respect of any Senior Obligations (after expiration of any applicable grace period) exceeding twenty-five million dollars ($25,000,000) in aggregate principal amount; 

(c) if the maturity of any Senior Obligations representing more than twenty-five million dollars ($25,000,000) in
aggregate principal amount is accelerated in accordance with its terms and such acceleration has not been rescinded; or 

(d) following the occurrence of any default (other than a payment default, and after the expiration of any applicable
grace period) with respect to any Senior Obligations with an aggregate principal amount of more than twenty-five million dollars ($25,000,000), the effect of which is to permit the holders of such Senior Obligations (or a trustee or agent acting on
their behalf) to cause, with the giving of notice if required, the maturity of such Senior Obligations to be accelerated, for a period commencing upon the receipt by the Trustee (with a copy to the Company) of a written notice of such default from
the representative of the holders of such Senior Obligations and ending when such Senior Obligations are paid in full in cash or cash equivalents or, if earlier, when such default is cured or waived. 

Section 10.4 When Distribution Must Be Paid Over. 

(a) In the event that the Trustee or any Holder receives any payment of any Junior Obligations at a time when such
payment is prohibited by this Article 10, such payment will be held by the Trustee or such Holder, in trust for the benefit of, and will be paid forthwith over and delivered, upon written request, to, the holders of Senior Obligations of the Company
as their interests may appear or their representative under the agreement, indenture or other document (if any) pursuant to which such Senior Obligations may have been issued, as their respective interests may appear, for application to the payment
of all such Senior Obligations remaining unpaid to the extent necessary to pay such Senior Obligations in full in accordance with their terms, after giving effect to any concurrent payment or distribution to or for the holders of Senior Obligations.

 (b) Any amount received by any Holder as a result of direct or indirect credit support for the Junior
Obligations from any Affiliate of the Company shall be treated as payments received by such Holder from the Company that are subject to the provisions of this Article 10. 
  

 46 

 (c) With respect to the holders of Senior Obligations, the Trustee
undertakes to perform only those obligations on the part of the Trustee as are specifically set forth in this Article 10, and no implied covenants or obligations with respect to the holders of Senior Obligations will be read into this CVR Agreement
against the Trustee. The Trustee will not be deemed to owe any fiduciary duty to the holders of Senior Obligations, and will not be liable to any such holders if the Trustee pays over or distributes to or on behalf of Holders or the Company or any
other Person money or assets to which any holders of Senior Obligations are then entitled by virtue of this Article 10, except if such payment is made as a result of the willful misconduct or gross negligence of the Trustee. 

Section 10.5 Notice by Company. The Company will promptly notify the Trustee of any facts known to the
Company that would cause a payment of any Junior Obligations to violate this Article 10, but failure to give such notice will not affect the subordination of the Junior Obligations to the Senior Obligations as provided in this Article 10.

 Section 10.6 Subordination Effective Notwithstanding Deficiencies with Respect to Senior Obligations;
Waiver of Right to Contest Senior Obligation; Reinstatement of Subordination Provisions. 
 (a) The Holders
hereby agree that subordination provisions contained in this Article 10 are unconditional, irrespective of the validity, regularity or enforceability of the Senior Obligations, the absence of any action to enforce the same, any waiver or consent by
any holder of Senior Obligations with respect to any provisions thereof, the recovery of any judgment against the Company, any action to enforce the same or any other circumstance which might otherwise constitute a legal or equitable discharge or
defense. Without limiting the foregoing, and notwithstanding anything to the contrary contained elsewhere in this CVR Agreement, in the event that the amount of Senior Obligations are reduced or diminished for any reason (other than as a result of
the payment in cash or cash equivalents thereof), whether because of the applicability of fraudulent conveyance or other applicable Laws, or any other invalidity or limitation on the amount of Senior Obligations, the subordination provisions thereof
shall apply to the full amount of Senior Obligations (without giving effect to any reduction, invalidity or diminution thereof), and the turnover provisions hereunder shall be fully enforceable with respect to the full amount of Senior Obligations
(without giving effect to any such reduction, invalidity or diminution thereof), even if the effect thereof is that there will be no (or a limited amount of) Senior Obligations to which the Junior Obligations are subrogated after the payment in full
in cash of any of then remaining Senior Obligations (without giving effect to any reductions, invalidity or diminution thereof, except for reductions as a result of payments thereof in cash or cash equivalents). 

(b) The Trustee and the Holders agree that they shall not (and hereby waive any right to) take any action to contest or
challenge (or assist or support any other Person in contesting or challenging), directly or indirectly, whether or not in any proceeding (including in any proceeding commenced by or against any Person under any provision of Title 11 of the United
States Code, as now and hereinafter in effect, or any successor statute or under any other state or federal bankruptcy or insolvency Law, assignments for the benefit of creditors, formal or informal moratoria, compositions, extensions generally with
creditors, or proceedings seeking 
  

 47 

 
reorganization, arrangement, or other similar relief), the validity or enforceability of the Senior Obligations. 

(c) If any payment made or in respect to the Senior Obligations must be disgorged or returned for any reason, the Senior
Obligations shall be reinstated hereunder and for all purposes of this Article 10 (including, without limitation, the turnover provisions hereof) such payment shall be deemed to have never been made with respect to the Senior Obligations.

 Section 10.7 Subrogation. After all Senior Obligations are paid in full in cash or cash
equivalents and until the Junior Obligations are paid in full, Holders will be subrogated to the rights of holders of Senior Obligations to receive distributions applicable to Senior Obligations to the extent that distributions otherwise payable to
the Holders have been applied to the payment of Senior Obligations. The Holders by accepting the Securities acknowledge that to the extent that the Senior Obligations are determined to be unenforceable, or the Senior Obligations are subordinated to
other obligations of the Company, such subrogation rights may be impaired. 
 Section 10.8 Relative
Rights. This Article 10 defines the relative rights of Holders and holders of Senior Obligations. Nothing in this CVR Agreement will: 

(a) impair, as between the Company and Holders, the obligations of the Company under this CVR Agreement and the
Securities; or 
 (b) affect the relative rights of Holders and creditors of the Company other than their rights
in relation to holders of Senior Obligations. 
 (c) If the Company fails because of this Article 10 to pay any
amounts due in respect of the Securities on a due date in violation of Section 8.1, the failure is still an Event of Default. 

Section 10.9 Subordination May Not Be Impaired by Company. No right of any holder of Senior Obligations to
enforce the subordination of the Junior Obligations may be impaired by any act or failure to act by the Company or any Holder or by the failure of the Company or any Holder to comply with this CVR Agreement. 

Section 10.10 Distribution or Notice to Representative. Whenever a distribution is to be made or a notice
given to holders of Senior Obligations, the distribution may be made and the notice given to their representative in accordance with the terms of the instrument or other agreement governing such Senior Obligations. Upon any payment or distribution
of assets of the Company referred to in this Article 10, the Trustee and the Holders will be entitled to rely upon any order or decree made by any court of competent jurisdiction or upon any certificate of such representative or of the liquidating
trustee or agent or other Person making any distribution to the Trustee or to the Holders for the purpose of ascertaining the Persons entitled to participate in such distribution, the holders of the Senior Obligations and other obligations of the
Company, the amount thereof or payable thereon, the amount or amounts paid or distributed thereon and all other facts pertinent thereto or to this Article 10. 
  

 48 

 Section 10.11 Rights of the Trustee. Notwithstanding the
provisions of this Article 10 or any other provision of this CVR Agreement, the Trustee will not be charged with knowledge of the existence of any facts that would prohibit the making of any payment or distribution by the Trustee, and the Trustee
may continue to make payments on the Securities, unless the Trustee has received at its address for notice specified in Section 1.5 at least five (5) Business Days prior to the date of such payment written notice of facts that would cause
the payment of any Junior Obligations to violate this Article 10. Only the Company or a representative of Senior Obligations may give the notice. Nothing in this Article 10 will impair the claims of, or payments to, the Trustee under or pursuant to
Section 4.7 hereof. The Trustee in its individual or any other capacity may hold Senior Obligations with the same rights it would have if it were not the Trustee. 

Section 10.12 Authorization to Effect Subordination. Each Holder, by the Holder’s acceptance of the
Securities, authorizes and directs the Trustee on such Holder’s behalf to take such action as may be necessary or appropriate to effectuate the subordination as provided in this Article 10, and appoints the Trustee to act as such Holder’s
attorney-in-fact for any and all such purposes. If the Trustee (or any other Person acting on behalf of and at the direction of the Majority Holders) does not file a proper proof of claim or proof of debt in the form required in any proceeding
referred to in Section 8.2 hereof at least thirty (30) days before the expiration of the time to file such claim, the representatives of the Senior Obligations are hereby authorized to file an appropriate claim for and on behalf of the
Holders of the Securities. 
 Section 10.13 Amendments. The provisions of this Article 10 are
expressly made for the benefit of the holders from time to time of the Senior Obligations, and may not be amended or modified without the written consent of the representatives of the holders of all Senior Obligations. 

ARTICLE 11 

REDEMPTION OF SECURITIES 

Section 11.1 Notice to Trustee. If the Company elects to redeem Securities pursuant to the optional
redemption provisions of Section 11.6 hereof, it shall furnish to the Trustee, at least forty five (45) days (unless a shorter period shall be agreed to by the Trustee) but not more than sixty (60) days before a redemption date (but
in any event prior to the notice provided pursuant to Section 11.3 hereof), an Officer’s Certificate (a “Consent and Purchase Offer”) setting forth (i) the clause of this CVR Agreement pursuant to which the redemption
shall occur, (ii) the redemption date, (iii) the amount of CVRs to be redeemed and (iv) the redemption price. 

Section 11.2 Selection of Securities to be Redeemed. If less than all of the Securities are to be redeemed or
purchased in a Consent and Purchase Offer at any time, the Trustee shall select the Securities to be redeemed or purchased among the Holders in compliance with the requirements of the principal national securities exchange, if any, on which the
Securities are listed or, if the Securities are not so listed, on a pro rata basis, by lot or in accordance with any other method the Trustee considers fair and appropriate. In the event of partial redemption by lot, the particular Securities to be
redeemed shall be selected, unless otherwise provided herein, not less than thirty (30) nor more than sixty (60) days prior to the 

 

 49 

 
redemption date by the Trustee from the outstanding Securities not previously called for redemption. The Trustee shall promptly notify the Company in writing of the Securities selected for
redemption or purchase. 
 Section 11.3 Notice of Redemption. At least thirty (30) days but not
more than sixty (60) days before a redemption date, the Company shall mail or cause to be mailed, by first class mail, a notice of redemption to each Holder whose Securities are to be redeemed at its registered address. The notice,
substantially in the form of Exhibit A hereto (the “Call Notice”), shall identify the amount of Securities to be redeemed and shall state: 

(a) the redemption date; 

(b) the redemption price; 

(c) the name and address of the paying agent; 

(d) that Securities called for redemption must be surrendered to the Paying Agent to collect the redemption price;

 (e) that, unless the Company defaults in making such redemption payment, all right title and interest in and
to the Securities and any Net Sales Payment, Milestone Payment or any other amounts due under this CVR Agreement, if any, on Securities called for redemption ceases to accrue on and after the redemption date; 

(f) the clause of this CVR Agreement pursuant to which the Securities called for redemption are being redeemed; and

 (g) that no representation is made as to the correctness or accuracy of the CUSIP and ISIN number, if any,
listed in such notice or printed on the Securities. 
 At the Company’s request, the Trustee shall give the
notice of redemption in the Company’s name and at its expense; provided, however, that the Company shall have delivered to the Trustee at least forty five (45) days (unless a shorter period shall be agreed to by the Trustee) but not more
than sixty (60) days prior to the redemption date, an Officer’s Certificate requesting that the Trustee give such notice and setting forth the information to be stated in such notice as provided in the preceding paragraph. 

Section 11.4 Effect of Notice of Redemption. Once notice of redemption is mailed in accordance with
Section 11.3 hereof, Securities called for redemption shall become irrevocably due and payable on the redemption date at the redemption price. A notice of redemption shall be deemed to be given when mailed, whether or not the Holder receives
the notice. In any event, failure to give such notice, or any defect in such notice, shall not affect the validity of the proceedings for the redemption of the Securities held by Holders to whom such notice was properly given. 

Section 11.5 Deposit of Redemption Price. On or one (1) Business Day prior to the redemption date, the
Company shall deposit with the Trustee or with the paying agent (if different from the Trustee) money sufficient to pay the redemption price of all Securities to be 

 

 50 

 
redeemed on that date. The Trustee or the paying agent shall promptly return to the Company any money deposited with the Trustee or the paying agent by the Company in excess of the amounts
necessary to pay the redemption price of all Securities to be redeemed. 
 If the Company complies with the provisions of the
preceding paragraph, on and after the redemption or purchase date, as applicable, all right title and interest of a Holder to any Net Sales Payment or Milestone Payment, if any, shall cease to accrue on the Securities called for redemption or
subject to purchase. If any Security called for redemption or subject to purchase shall not be so paid upon surrender for redemption or purchase because of the failure of the Company to comply with the preceding paragraph, interest shall be paid on
the unpaid redemption price from the redemption date or Purchase Date, as applicable, until such redemption price is paid at the Shortfall Interest Rate. 

Section 11.6 Optional Redemption by the Company. The Company may, at any time on and after the Redemption
Eligibility Date, redeem all (but not less than all) of the outstanding Securities at a cash redemption price equal to the average price paid per Security for all Securities previously purchased by the Company calculated as of the Business Day
immediately prior to the date of the Call Notice mailed by the Company in accordance with Section 11.3 hereof. 
  

 51 

 IN WITNESS WHEREOF, the Parties hereto have caused this CVR Agreement to be duly executed,
all as of the day and year first above written. 
  

			
	CELGENE CORPORATION
		
	By:	 	  

		 	Name:
		 	Title:
	
	 [—],

as the Trustee

		
	By:	 	  

		 	Name:
		 	Title:

  

 52 

 CELGENE CORPORATION 

 

					
	No.	  	Certificate for	  	Contingent Value Rights

This certifies that
                    , or registered assigns (the “Holder”), is the registered holder of the number of Contingent Value Rights
(“CVRs” or “Securities”) set forth above. Each CVR entitles the Holder, subject to the provisions contained herein and in the CVR Agreement referred to on the reverse hereof, to payments from Celgene Corporation, a
Delaware corporation (the “Company”), in an amounts and in the forms determined pursuant to the provisions set forth on the reverse hereof and as more fully described in the CVR Agreement referred to on the reverse hereof. Such
payments shall be made on a Payment Date, as defined in the CVR Agreement referred to on the reverse hereof. 

Payment of any amounts pursuant to this CVR Certificate shall be made only to the registered Holder (as defined in the
CVR Agreement) of this CVR Certificate. Such payment shall be made in the Borough of Manhattan, The City of New York, or at any other office or agency maintained by the Company for such purpose, in such coin or currency of the United States of
America as at the time is legal tender for the payment of public and private debts; provided, however, the Company may pay such amounts by wire transfer or check payable in such money. [TRUSTEE] has been initially appointed as Paying Agent at its
office or agency in the Borough of Manhattan, The City of New York. 
 Reference is hereby made to the further
provisions of this CVR Certificate set forth on the reverse hereof, which further provisions shall for all purposes have the same effect as if set forth at this place. 

Unless the certificate of authentication hereon has been duly executed by the Trustee referred to on the reverse hereof
by manual signature, this CVR Certificate shall not be entitled to any benefit under the CVR Agreement, or be valid or obligatory for any purpose. 

IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed. 

 

							
	Dated:	 	[—]	 	
				
		 	By:	 	  
	 	
		 	Name:	 	
		 	Title:	 	

  

			
	Attest:	 	
	
	  

	Authorized Signature

  

 A-1 

 [Form of Reverse of CVR Certificate] 

1. This CVR Certificate is issued under and in accordance with the Contingent Value Rights Agreement, dated as of
[—], 2010 (the “CVR Agreement”), between the Company and [—], a national banking association, as trustee (the
“Trustee,” which term includes any successor Trustee under the CVR Agreement), and is subject to the terms and provisions contained in the CVR Agreement, to all of which terms and provisions the Holder of this CVR Certificate
consents by acceptance hereof. The CVR Agreement is hereby incorporated herein by reference and made a part hereof. Reference is hereby made to the CVR Agreement for a full statement of the respective rights, limitations of rights, duties,
obligations and immunities thereunder of the Company, the Trustee and the Holders of the CVRs. All capitalized terms used in this CVR Certificate without definition shall have the respective meanings ascribed to them in the CVR Agreement. Copies of
the CVR Agreement can be obtained by contacting the Trustee. 
 2. On each Net Sales Payment Date, the Company
shall pay to the Holder hereof, for each CVR represented hereby, a pro rata portion of the Net Sales Payment, if any, with respect to the Net Sales Measuring Period ended immediately prior to such Net Sales Payment Date. 

3. In the event of any conflict between this CVR Certificate and the CVR Agreement, the CVR Agreement shall govern and
prevail. 
 4. Subject to the terms and conditions of the CVR Agreement, on each Milestone Payment Date (or, in
any such case, if such day is not a Business Day, without accruing any interest, on the next succeeding Business Day), the Company shall pay to the Holder hereof, for each CVR represented hereby, a pro rata portion of the applicable Milestone
Payment with respect to the occurrence of a Milestone. 
 5. Each CVR Payment, if any, and interest thereon, if
any, shall be payable by the Company in such coin or currency of the United States of America as at the time is legal tender for the payment of public and private debts; provided, however, the Company may pay such amounts by its check or wire
transfer payable in such money. [TRUSTEE] has been initially appointed as Paying Agent at its office or agency in the Borough of Manhattan, The City of New York. 

6. If an Event of Default occurs and is continuing, either the Trustee may or the Majority Holders, by notice to the
Company and to the Trustee shall bring suit in accordance with the terms and conditions of the CVR Agreement to protect the rights of the Holders, including to obtain payment of all amounts then due and payable, with interest at the Default Interest
Rate from the date of the Event of Default through the date payment is made or duly provided for. 
 7. No
reference herein to the CVR Agreement and no provision of this CVR Certificate or of the CVR Agreement shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay any amounts determined pursuant to the terms
hereof and of the CVR Agreement at the times, place and amount, and in the manner, herein prescribed. 
  

 A-2 

 8. Each CVR Payment or any other right, claim or payment of any kind under
this CVR Certificate, if any, shall be subordinated in right of payment, as set forth in Article 10 of the CVR Agreement, to the prior payment in full in cash or cash equivalents of all Senior Obligations whether outstanding on the date of the CVR
Agreement or thereafter incurred. 
 9. As provided in the CVR Agreement and subject to certain limitations
therein set forth, the transfer of the CVRs represented by this CVR Certificate is registrable on the Security Register, upon surrender of this CVR Certificate for registration of transfer at the office or agency of the Company maintained for such
purpose in the Borough of Manhattan, The City of New York, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or his attorney duly
authorized in writing, and thereupon one or more new CVR Certificates, for the same amount of CVRs, will be issued to the designated transferee or transferees. The Company hereby initially designates the office of [TRUSTEE] at
[—] as the office for registration of transfer of this CVR Certificate. 

10. As provided in the CVR Agreement and subject to certain limitations therein set forth, this CVR Certificate is
exchangeable for one or more CVR Certificates representing the same number of CVRs as represented by this CVR Certificate as requested by the Holder surrendering the same. 

11. No service charge will be made for any registration of transfer or exchange of CVRs, but the Company may require
payment of a sum sufficient to cover all documentary, stamp or similar issue or transfer taxes or other governmental charges payable in connection with any registration of transfer or exchange. 

12. Prior to the time of due presentment of this CVR Certificate for registration of transfer, the Company, the Trustee
and any agent of the Company or the Trustee may treat the Person in whose name this CVR Certificate is registered as the owner hereof for all purposes, and neither the Company, the Trustee nor any agent shall be affected by notice to the contrary.

 13. Neither the Company nor the Trustee has any duty or obligation to the holder of this CVR Certificate,
except as expressly set forth herein or in the CVR Agreement. 
 14. Redemption. 

(a) Notice to Trustee. If the Company elects to redeem Securities pursuant to the optional redemption provisions
of Section 11.6 of the CVR Agreement, it shall furnish to the Trustee, at least forty five (45) days (unless a shorter period shall be agreed to by the Trustee) but not more than sixty (60) days before a redemption date (but in any
event prior to the notice provided pursuant to Section 11.3 of the CVR Agreement), an Officer’s Certificate (a “Consent and Purchase Offer”) setting forth (i) the clause of the CVR Agreement pursuant to which the
redemption shall occur, (ii) the redemption date, (iii) the amount of CVRs to be redeemed and (iv) the redemption price. 
  

 A-3 

 (b) Selection of Securities to be Redeemed. If less than all of the
Securities are to be redeemed or purchased in a Consent and Purchase Offer at any time, the Trustee shall select the Securities to be redeemed or purchased among the Holders in compliance with the requirements of the principal national securities
exchange, if any, on which the Securities are listed or, if the Securities are not so listed, on a pro rata basis, by lot or in accordance with any other method the Trustee considers fair and appropriate. In the event of partial redemption by lot,
the particular Securities to be redeemed shall be selected, unless otherwise provided herein, not less than thirty (30) nor more than sixty (60) days prior to the redemption date by the Trustee from the outstanding Securities not
previously called for redemption. The Trustee shall promptly notify the Company in writing of the Securities selected for redemption or purchase. 

(c) Notice of Redemption. At least thirty (30) days but not more than sixty (60) days before a
redemption date, the Company shall mail or cause to be mailed, by first class mail, a notice of redemption to each Holder whose Securities are to be redeemed at its registered address. The notice, substantially in the form of Exhibit A of the CVR
Agreement (the “Call Notice”), shall identify the amount of Securities to be redeemed and shall state: 

(i) the redemption date; 

(ii) the redemption price; 

(iii) the name and address of the paying agent; 

(iv) that Securities called for redemption must be surrendered to the Paying Agent to collect the
redemption price; 
 (v) that, unless the Company defaults in making such redemption payment, all right title
and interest in and to the Securities and any Net Sales Payment, Milestone Payment or any other amounts due under the CVR Agreement, if any, on Securities called for redemption ceases to accrue on and after the redemption date; 

(vi) the clause of the CVR Agreement pursuant to which the Securities called for redemption are being redeemed; and

 (vii) that no representation is made as to the correctness or accuracy of the CUSIP and ISIN number, if any,
listed in such notice or printed on the Securities. 
 At the Company’s request, the Trustee shall give the notice of
redemption in the Company’s name and at its expense; provided, however, that the Company shall have delivered to the Trustee at least forty five (45) days (unless a shorter period shall be agreed to by the Trustee) but not more than sixty
(60) days prior to the redemption date, an Officer’s Certificate requesting that the Trustee give such notice and setting forth the information to be stated in such notice as provided in the preceding paragraph. 

 

 A-4 

 (d) Effect of Notice of Redemption. Once notice of redemption is
mailed in accordance with Section 11.3 of the CVR Agreement, Securities called for redemption shall become irrevocably due and payable on the redemption date at the redemption price. A notice of redemption shall be deemed to be given when
mailed, whether or not the Holder receives the notice. In any event, failure to give such notice, or any defect in such notice, shall not affect the validity of the proceedings for the redemption of the Securities held by Holders to whom such notice
was properly given. 
 (e) Deposit of Redemption Price. On or one (1) Business Day prior to the
redemption date, the Company shall deposit with the Trustee or with the paying agent (if different from the Trustee) money sufficient to pay the redemption price of all Securities to be redeemed on that date. The Trustee or the paying agent shall
promptly return to the Company any money deposited with the Trustee or the paying agent by the Company in excess of the amounts necessary to pay the redemption price of all Securities to be redeemed. 

If the Company complies with the provisions of the preceding paragraph, on and after the redemption or purchase date, as applicable, all right title and
interest of a Holder to any Net Sales Payment or Milestone Payment, if any, shall cease to accrue on the Securities called for redemption or subject to purchase. If any Security called for redemption or subject to purchase shall not be so paid upon
surrender for redemption or purchase because of the failure of the Company to comply with the preceding paragraph, interest shall be paid on the unpaid redemption price from the redemption date or Purchase Date, as applicable, until such redemption
price is paid at the Shortfall Interest Rate. 
 (f) Optional Redemption by the Company. The Company
may, at any time on and after the Redemption Eligibility Date, redeem all (but not less than all) of the outstanding Securities at a cash redemption price equal to the average price paid per Security for all Securities previously purchased by the
Company calculated as of the Business Day immediately prior to the date of the Call Notice mailed by the Company in accordance with Section 11.3 of the CVR Agreement. 
  

 A-5 

 TRUSTEE’S CERTIFICATE OF AUTHENTICATION 

This is one of the CVR Certificates referred to in the within-mentioned CVR Agreement. 

 

									
		 		 		 	 [—],

as the Trustee

					
	Dated:	 	  
	 		 	By	 	  

		 		 		 		 	Authorized Signatory

  

 A-6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00175-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00175-of-00352.parquet"}]]